{"gene":"GATA2","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2011,"finding":"Heterozygous GATA2 missense mutations (p.Thr354Met, p.Thr355del) within the second zinc finger domain reduce DNA-binding affinity and transactivation of target genes, and differentially affect cellular differentiation and apoptosis, establishing haploinsufficiency as a mechanism of MDS-AML predisposition.","method":"Functional transactivation assays, cellular differentiation assays, apoptosis assays, global gene expression profiling of patient-derived mutations","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal functional assays (transactivation, differentiation, apoptosis, gene expression) in a peer-reviewed study identifying the founding mutations","pmids":["21892162"],"is_preprint":false},{"year":1995,"finding":"GATA2 is phosphorylated in hematopoietic progenitor cells; IL-3 stimulation enhances GATA2 phosphorylation within 5 minutes via the MAP kinase pathway, as demonstrated by constitutively activating and interfering MAP kinase kinase mutants; in vitro phosphorylation experiments raise the possibility that MAP kinase directly phosphorylates GATA2.","method":"In vivo phosphorylation assays in hematopoietic progenitors, genetic manipulation of MAP kinase pathway in COS cells (activating/interfering MEK mutants), in vitro phosphorylation with recombinant GATA2","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro kinase assay plus genetic epistasis in cells; two orthogonal approaches (genetic MEK manipulation + in vitro phosphorylation) from a single lab","pmids":["7876160"],"is_preprint":false},{"year":2007,"finding":"GATA2 expression oscillates during the cell cycle in hematopoietic cells (high in S phase, low in G1/S and M phase) due to proteasome-dependent degradation regulated by phosphorylation at Cdk-consensus (S/T-P) motifs; GATA2 physically interacts with Cdk2/cyclin A2 and Cdk4/cyclin D1 complexes and is phosphorylated by these in vitro; mutations at phosphorylation motifs alter cell-cycle-specific GFP-GATA2 expression profiles.","method":"Cell-cycle synchronization, GFP-GATA2 fusion protein imaging, immunoprecipitation/immunoblotting for Cdk interactions, in vitro phosphorylation by Cdk/cyclin, phosphorylation-site mutagenesis, proteasome inhibition","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods: in vitro kinase assay, Co-IP with Cdks, mutagenesis of phosphorylation sites, and proteasome inhibition; single lab but mechanistically comprehensive","pmids":["17255359"],"is_preprint":false},{"year":2007,"finding":"Gata2, Fli1, and Scl/Tal1 form a fully connected recursive gene-regulatory circuit (triad) in hematopoietic stem cells; each of these transcription factors binds the enhancers of the other two (Gata2-3, Fli1+12, Scl+19) in embryonic dorsal aorta, fetal liver, and ES cell-derived hemangioblast equivalents.","method":"Chromatin immunoprecipitation (ChIP) at multiple HSC enhancers, enhancer-reporter transgenic mice, cis-element motif analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal ChIP across three loci in multiple tissue contexts, validated by transgenic reporter assays; replicated across enhancer elements","pmids":["17962413"],"is_preprint":false},{"year":2006,"finding":"GATA2 is a direct transcriptional target of BMP4 in hemangioblast development; enforced GATA2 expression upregulates Bmp4, Flk1, and Scl; conditional GATA2 induction increases hemangioblast generation and endothelial cell production and confers a proliferative signal to primitive erythroid progenitors in a temporal-sensitive manner.","method":"ES cell differentiation system, conditional GATA2 induction, gene expression analysis, BMP4 stimulation experiments","journal":"Development (Cambridge, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional gain-of-function with defined cellular phenotypes and upstream pathway placement; single lab","pmids":["17166922"],"is_preprint":false},{"year":2008,"finding":"GATA2 regulates granulocyte-macrophage progenitor (GMP) function through transcriptional activation of HES-1; GATA2 binds the HES-1 locus in myeloid progenitor cells, and enforced HES-1 expression in GATA2-heterozygous GMPs rescues the functional defect caused by GATA2 haploinsufficiency.","method":"GATA2+/- mouse analysis, RNA interference knockdown, colony-forming assays, competitive transplantation, ChIP at HES-1 locus, HES-1 forced expression rescue","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP at HES-1 locus, epistasis rescue experiment, genetic heterozygous model, and RNAi; multiple orthogonal methods","pmids":["18840712"],"is_preprint":false},{"year":2013,"finding":"GATA2 function is essential for endothelial-to-hematopoietic transition (EHT) during HSC generation from VE-Cadherin-expressing endothelial cells, and is also required for HSC survival after generation in Vav-expressing hematopoietic cells; these two roles are genetically separable and distinct from RUNX1 function.","method":"Conditional Gata2 deletion using Vec-Cre (endothelial) and Vav-Cre (hematopoietic) lineage-specific mouse models, long-term repopulation assays, intra-aortic cluster analysis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent conditional KO systems with lineage-specific deletion, functional HSC assays (LT-repopulation), and epistatic comparison to RUNX1","pmids":["24297996"],"is_preprint":false},{"year":2012,"finding":"GATA2 loss in VE-enhancer-expressing endothelial cells causes anemia via HSC loss in fetal liver and defective lymphatic vascular development; the VE enhancer also regulates GATA2 expression in definitive fetal liver and adult bone marrow HSCs.","method":"Tamoxifen-inducible Cre transgenic mice (Gata2 VECre), in vitro colony-forming assays, immunophenotyping, in vivo long-term competitive repopulation, embryo morphology analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — inducible conditional KO with multiple functional readouts (colony, repopulation, lymphatic phenotype); rigorous mechanistic dissection","pmids":["22996665"],"is_preprint":false},{"year":2014,"finding":"GATA2 directly promotes expression of both full-length and splice-variant androgen receptor (AR) in prostate cancer; GATA2 co-localizes with AR and FOXA1 on chromatin and enhances recruitment of steroid receptor coactivators (SRC) and formation of the transcriptional holocomplex; AR/androgen negatively regulates GATA2 in a feedback loop.","method":"ChIP, gene expression profiling, Co-IP, knockdown/overexpression experiments in prostate cancer cell lines, patient specimen correlation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating co-occupancy with AR and FOXA1, coactivator recruitment assays, and KD/OE with defined molecular phenotypes; single lab with multiple orthogonal methods","pmids":["25489091"],"is_preprint":false},{"year":2013,"finding":"GATA2 and LMO2 form transcriptional complexes in endothelial and lymphatic endothelial cells and cooperatively regulate VEGF-induced angiogenesis and lymphangiogenesis by directly activating neuropilin-2 (NRP2) gene expression at the promoter level; NRP2 overexpression partially rescues impaired angiogenic sprouting caused by GATA2/LMO2 knockdown.","method":"siRNA knockdown, lentiviral overexpression, angiogenic sprouting assays, NRP2 promoter analysis, NRP2 rescue experiments in endothelial and lymphatic endothelial cells","journal":"Angiogenesis","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — functional rescue experiment with NRP2, promoter analysis, and KD phenotype; single lab with multiple assays","pmids":["23892628"],"is_preprint":false},{"year":2014,"finding":"Etv2 and Gata2 physically interact in vitro and in vivo; the protein-protein interaction is mediated by the Ets and GATA domains; co-expression of Gata2 augments Etv2 activity in promoting endothelial and hematopoietic lineage differentiation; Etv2 and Gata2 both bind the Spi1 promoter in vitro and in vivo.","method":"Co-immunoprecipitation in vitro and in vivo, embryoid body differentiation system, ChIP at Spi1 promoter, domain-deletion interaction mapping","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus ChIP for shared target; single lab, two orthogonal methods","pmids":["24583263"],"is_preprint":false},{"year":2015,"finding":"STAT5 directly binds the Gata2 promoter and an intronic region, transcriptionally activating Gata2; overexpression of Gata2 alone is sufficient to direct basophil and mast cell differentiation in the absence of Stat5, establishing GATA2 as a downstream effector in the STAT5-GATA2 pathway for basophil and mast cell differentiation.","method":"ChIP of STAT5 at Gata2 locus, Gata2 overexpression in Stat5-deficient cells, conditional knockout mice, differentiation assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP demonstrating direct STAT5 binding to Gata2 locus, genetic epistasis (rescue by Gata2 overexpression in Stat5-/- cells); multiple orthogonal methods","pmids":["25801432"],"is_preprint":false},{"year":2015,"finding":"GATA2 regulates erythroid maturation through transcriptional repression of Gata2 by histone methyltransferase Setd8 (which monomethylates H4K20); Setd8 occupies regulatory elements in the Gata2 locus, and Setd8 knockdown leads to loss of H4K20me1 and gain of H4 acetylation at the Gata2 1S promoter, increasing GATA2 expression; Gata2 knockdown rescues maturation impairments caused by Setd8 disruption.","method":"Stable Setd8 knockdown in erythroblasts, global gene expression, ChIP for Setd8 occupancy and histone marks at Gata2 locus, Gata2 knockdown rescue experiments","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP for occupancy and histone marks at Gata2 locus, genetic rescue by Gata2 KD, and phenotypic characterization; multiple orthogonal methods from single lab","pmids":["25848090"],"is_preprint":false},{"year":2016,"finding":"Uterine GATA2 directly occupies and promotes expression of the progesterone receptor (PGR) gene and co-regulates downstream progesterone-responsive genes in conjunction with PGR; uterine-specific Gata2 ablation causes infertility via impaired embryo implantation, decidualization failure, reduced PGR expression, and attenuated progesterone signaling.","method":"Uterine-specific conditional Gata2 knockout mice, genome-wide ChIP-seq (GATA2 occupancy at Pgr locus), RNA-seq, implantation and decidualization phenotyping","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with ChIP-seq and RNA-seq demonstrating direct GATA2 occupancy at Pgr and co-regulation of PGR target genes","pmids":["27783953"],"is_preprint":false},{"year":2016,"finding":"GATA2 deficiency in endothelial cells causes vascular abnormalities through regulation of miR-126 (pro-angiogenic) and miR-221 (anti-angiogenic); GATA2 transcriptionally activates miR-126 (which targets SPRED1 and FOXO3a) and suppresses miR-221 expression via DNA methylation of the miR-221 promoter CpG island; miR-221 silencing or miR-126 supplementation reverses the GATA2-deficient vascular phenotype.","method":"Endothelial siRNA knockdown and lentiviral overexpression, ChIP, luciferase promoter assays, bisulfite sequencing, proteome profiler, luciferase reporter gene assays, carotid injury mouse model with nanoparticle miR-126 delivery","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP, promoter luciferase assays, bisulfite sequencing, and in vivo mouse rescue; multiple orthogonal methods in single study","pmids":["27780851"],"is_preprint":false},{"year":2016,"finding":"GATA2 is required for DC differentiation via the myeloid pathway; GATA2 binds an enhancer element 190-kb downstream of the Gata3 locus and represses Gata3 expression in DC progenitors; loss of GATA2 leads to reduced myeloid gene expression (including mafb) and increased T-lymphocyte gene expression (including Gata3 and Tcf7) in DC progenitors.","method":"Gata2 conditional knockout and haploinsufficient mice, in vitro DC generation from progenitors, expression profiling, luciferase reporter assay with Gata3 +190 enhancer and GATA sequence deletion","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with in vitro rescue, reporter assay with mutagenesis of GATA binding sites, and expression profiling; multiple orthogonal methods","pmids":["27259979"],"is_preprint":false},{"year":2017,"finding":"GATA2 missense mutations in zinc finger 2 (gT354M, gR396Q, gR398W, gC373R) display reduced DNA-binding affinity and transactivation compared to wild-type; two mutants (gT354M and gC373R) bind PU.1 more strongly than wild-type GATA2, potentially perturbing differentiation through PU.1 sequestration; all mutants except sL359V fail to suppress colony formation and some skew cell fate to granulocytes.","method":"DNA-binding affinity assays, transactivation reporter assays, Co-immunoprecipitation with PU.1, colony formation assays, cell fate analysis","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro DNA-binding assay, Co-IP for PU.1 interaction, functional transactivation, and colony/differentiation assays; multiple orthogonal methods in single study","pmids":["28642594"],"is_preprint":false},{"year":2018,"finding":"GATA2 N-finger (amino-terminal zinc finger) mutations decrease GATA2 chromatin occupancy and attenuate target gene regulation; in a genetic complementation assay in myeloid progenitors, GATA2 disease mutants fail to induce erythroid differentiation but unexpectedly promote myeloid differentiation and proliferation, indicating GATA2 mutations are not strictly loss-of-function and that haploinsufficiency does not fully explain pathogenesis.","method":"Genetic complementation assay in Gata2 -77 enhancer-mutant mouse myeloid progenitors, chromatin occupancy assays, erythroid and myeloid differentiation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic complementation assay with multiple GATA2 mutants tested for chromatin occupancy and differentiation phenotypes; mechanistically rigorous with multiple orthogonal readouts","pmids":["30301799"],"is_preprint":false},{"year":2019,"finding":"A single-nucleotide mutation in the Ets motif of the GATA2 +9.5 intronic enhancer does not impair steady-state hematopoiesis but abrogates stem/progenitor cell regeneration following hematopoietic stress, revealing that a disease predisposition mutation can selectively inactivate enhancer regenerative activity while sparing developmental activity.","method":"Mouse knockin models of +9.5 enhancer Ets motif mutations, steady-state hematopoiesis analysis, stress-induced hematopoietic regeneration assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knockin mouse model with functional dissection of steady-state vs. stress hematopoiesis; well-controlled mechanistic study","pmids":["30620726"],"is_preprint":false},{"year":2019,"finding":"GATA2 and PU.1 cooperatively activate Ms4a2 (FcεRIβ) gene expression in mast cells through distinct mechanisms: GATA2 exclusively binds the proximal -60-bp promoter region in a mast cell-specific manner, while both GATA2 and PU.1 share binding at a +10.4-kbp downstream enhancer with LDB1; PU.1 ablation reduces GATA2 binding at both sites; deletion of the +10.4-kbp region by genome editing completely abolishes Ms4a2 expression.","method":"ChIP-seq, siRNA knockdown, genome editing (deletion of +10.4-kbp enhancer), chromatin looping analysis, mast cell gene expression assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq, genome editing with complete functional ablation, KD epistasis; multiple orthogonal methods","pmids":["31501274"],"is_preprint":false},{"year":2019,"finding":"GATA2 controls lymphatic vascular development and lymphovenous valve morphogenesis by regulating expression of miR-126, which in turn controls cell junction molecules VE-cadherin and claudin 5; miR-126 overexpression in GATA2-depleted lymphatic endothelial cells significantly rescues cell junction defects.","method":"Conditional GATA2 knockout mouse, primary human lymphatic endothelial cell (HLEC) siRNA knockdown, miR-126 overexpression rescue, junction molecule immunostaining","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO in vivo plus in vitro HLEC KD with miR-126 rescue; multiple orthogonal models","pmids":["31582413"],"is_preprint":false},{"year":2020,"finding":"GATA2 deletion of the murine -77 enhancer (human equivalent causes leukemia) downregulates GATA2 and blocks progenitor differentiation into erythrocytes, megakaryocytes, basophils, and granulocytes (but not macrophages); multiomics and single-cell analyses show the enhancer coordinates both pro-fate and anti-fate (innate immunity-linked) circuitry in individual progenitor cells; increasing GATA2 via the enhancer both promotes fate and abrogates a fate-suppressing innate immunity program.","method":"Murine Gata2 -77 enhancer deletion, multiomics (transcriptomics + chromatin), single-cell analysis, progenitor differentiation assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal -omics plus functional differentiation assays in well-validated enhancer-mutant model","pmids":["32736380"],"is_preprint":false},{"year":2020,"finding":"GATA2 directly activates CGA transcription; secreted CGA binds EGFR and activates EGFR signaling conferring chemoresistance; EGFR signaling in turn induces GATA2 expression and phosphorylation, forming a positive feedback circuit; N-glycosylation of CGA at Asn52 and Asn78 is required for CGA stability, secretion, and EGFR interaction.","method":"Secretome screening, conditioned media experiments, EGFR signaling assays, GATA2 overexpression/knockdown, mutagenesis of CGA N-glycosylation sites, ChIP for GATA2 at CGA promoter, microRNA target assays","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for GATA2 at CGA promoter, epistatic circuit demonstrated by KD/OE and mutagenesis; single lab","pmids":["35289315"],"is_preprint":false},{"year":2021,"finding":"GATA2 promotes chromatin accessibility at super-enhancers of mast cell identity genes and primes both typical and super-enhancers at genes that respond to antigenic stimulation; GATA2-bound sites are several-fold denser at super-enhancers than at typical enhancers in mast cells.","method":"GATA2 knockout mast cells, ATAC-seq, ChIP-seq for GATA2 binding at super-enhancers and typical enhancers, RNA-seq","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ATAC-seq and ChIP-seq in KO cells with RNA-seq; multiple orthogonal genomic methods","pmids":["33479210"],"is_preprint":false},{"year":2022,"finding":"HMGA1 transactivates GATA2 through sequences near the +9.5 developmental enhancer, increasing chromatin accessibility and recruiting active histone marks; silencing GATA2 recapitulates most phenotypes of HMGA1 depletion in MPN cells, and GATA2 re-expression partially rescues leukemogenesis after HMGA1 loss.","method":"CRISPR/Cas9 disruption, shRNA knockdown, RNA-seq, ChIP-seq (HMGA1 occupancy at +9.5 GATA2 enhancer), chromatin accessibility assays, GATA2 rescue experiments","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq at GATA2 enhancer, genetic rescue with GATA2 re-expression, KD/KO with multiple phenotypic readouts","pmids":["35286385"],"is_preprint":false},{"year":2023,"finding":"GATA2 undergoes mitotic bookmarking via C-terminal zinc finger-mediated DNA binding, remaining bound to chromatin throughout mitosis in contrast to GFI1B and FOS; it bookmarks a subset of interphase targets co-enriched for RUNX1; conditional GATA2 degradation at mitotic exit in mice (cyclin B1 degradation domain knockin) abolishes definitive haematopoiesis at AGM, placenta, and fetal liver without impairing yolk sac haematopoiesis.","method":"Live-cell imaging, GATA2-cyclin B1 degradation domain knockin mouse model, ChIP during mitosis vs. interphase, domain-deletion experiments (C-terminal zinc finger), multiomics","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knockin mouse model plus mechanistic dissection of ZF domain requirement and genome-wide chromatin occupancy during mitosis; multiple orthogonal methods","pmids":["37580379"],"is_preprint":false},{"year":2009,"finding":"GATA2 positively autoregulates its own transcription in the mouse midbrain through two discrete promoter domains (5H at -3.0 kbp and 2H at -1.9 kbp upstream of TSS) that both contain GATA factor binding sites; GATA2 (but not GATA3) is essential for Gata2 gene expression in the midbrain.","method":"Transgenic reporter mice, in vivo deletion analysis of promoter domains, Gata2/Gata3 knockout analyses, domain-specific reporter constructs","journal":"Genes to cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo transgenic reporter assay with genetic KO epistasis; single lab","pmids":["19371385"],"is_preprint":false},{"year":2017,"finding":"GATA2 directly binds to the SEMA3C androgen response element in a GATA2-dependent manner, and AR-mediated transcriptional activation of SEMA3C requires GATA2; FOXA1 is a negative regulator of SEMA3C expression in the same context.","method":"ChIP for GATA2 and AR at SEMA3C locus, GATA2 knockdown in LNCaP cells, androgen stimulation experiments, luciferase reporter assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and KD with defined target gene phenotype; single lab, two methods","pmids":["28038451"],"is_preprint":false},{"year":2013,"finding":"GATA2 directly represses GATA6 expression in gastric cancer cells by recruiting the PRC2 complex to the GATA6 locus; disruption of GATA2 expression impairs PRC2 recruitment and results in GATA6 upregulation; GATA2 and PRC2 complexes are enriched within the GATA6 locus as demonstrated by ChIP.","method":"ChIP for GATA2 and PRC2 at GATA6 locus, GATA2 overexpression and knockdown, ectopic expression, bisulfite methylation analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating co-occupancy and epistatic KD/OE; single lab","pmids":["29106391"],"is_preprint":false},{"year":2020,"finding":"GATA2 transcriptionally activates the Gata2 locus in endothelial haemogenic cells partly through the i4 pan-endothelial enhancer in zebrafish; deletion of the i4 enhancer reduces Gata2a, which in turn reduces runx1 and gata2b expression in hemogenic endothelium, and recovery is mediated by Notch signalling.","method":"CRISPR/Cas9 deletion of i4 enhancer in zebrafish, expression analysis of runx1/gata2b, Notch pathway analysis, adult hematopoiesis phenotyping","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo enhancer deletion with epistatic analysis of downstream targets; single lab","pmids":["32054973"],"is_preprint":false},{"year":2017,"finding":"In vivo time-lapse imaging reveals that Gata2 reporter expression shows rapid pulsatile level changes in individual cells undergoing endothelial-to-hematopoietic transition (EHT) in the aorta; Gata2 haploinsufficient cells exhibit fewer transitions and reduced hematopoietic potential, suggesting threshold levels of Gata2 control fate establishment.","method":"Gata2Venus knock-in reporter mouse, time-lapse live imaging of aortic cells during EHT, single-cell quantitative fluorescence analysis, comparison with Gata2 heterozygous aortic cells","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct live imaging of endogenous GATA2 dynamics in single cells during fate transition, with functional comparison to haploinsufficient cells; novel mechanistic insight with direct experimental evidence","pmids":["29217535"],"is_preprint":false},{"year":2025,"finding":"GATA2 transcriptionally regulates RASSF4, a modulator of the p53 inhibitor MDM2, thereby dampening p53-mediated apoptosis; GATA2 deletion results in more robust p53 induction after doxorubicin exposure; RASSF4 and GATA2 are anticorrelated in AML; knockdown of Rassf4 in Gata2-low cells confers doxorubicin resistance; overexpression of Rassf4 sensitizes Gata2-high cells.","method":"ChIP-seq, RNA-seq, GATA2 deletion (CRISPR/Cas9), Rassf4 knockdown and overexpression, doxorubicin sensitivity assays, nutlin-3 experiments, single-cell and bulk patient expression data","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq demonstrating direct GATA2 binding at RASSF4 locus, genetic epistasis (Gata2 KO + Rassf4 KD/OE), functional drug resistance assays; multiple orthogonal methods","pmids":["39841459"],"is_preprint":false},{"year":2013,"finding":"Progesterone receptor B (PGR-B) drives Ednra gene activation through one of six progesterone response elements (PRE6) in a conserved upstream region; GATA2 activity at a GATA2 site in the same region is required for the progesterone response, and GATA2 synergizes with PGR-B to enhance Ednra expression.","method":"In vivo pregnancy/progesterone experiments, promoter deletion analysis, luciferase reporter assays, GATA2 site mutagenesis","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter assays with GATA2 site mutagenesis and in vivo validation; single lab","pmids":["23592430"],"is_preprint":false},{"year":2019,"finding":"GATA2 is not required for VE-cadherin+CD43-CD73- hemogenic endothelium (HE) specification or HE diversification into DLL4+ arterial and DLL4- non-arterial lineages, but is primarily required for HE to undergo endothelial-to-hematopoietic transition (EHT); forced GATA2 expression in non-HE failed to induce blood formation.","method":"GATA2 knockout hESC lines with conditional GATA2 expression (iG2-/- hESCs), hematopoietic differentiation assays, flow cytometry for HE and hematopoietic progenitor phenotypes","journal":"Stem cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO in human ESCs with rescue and gain-of-function, defining specific developmental stage of GATA2 requirement","pmids":["29861167"],"is_preprint":false},{"year":2021,"finding":"GATA2 functions as a tumor suppressor in acute promyelocytic leukemia (APL); biallelic Gata2 knockout by CRISPR/Cas9 increases serial replating efficiency of PML-RARA-expressing progenitors, increases APL penetrance, and decreases latency; restoration of Gata2 suppresses PML-RARA-driven aberrant self-renewal; a mutant GATA2-R362G (associated with APL/AML) minimally suppresses PML-RARA-induced self-renewal, indicating it is a loss-of-function mutation.","method":"CRISPR/Cas9 Gata2 biallelic knockout, serial replating assays, mouse leukemia model (penetrance/latency), Gata2 restoration experiments, mutant addback experiments","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — biallelic KO with CRISPR, in vivo leukemia model, rescue by WT and mutant addback; multiple orthogonal approaches","pmids":["34125173"],"is_preprint":false},{"year":2019,"finding":"GATA2 hypomorphism (reduced Gata2 expression by neocassette insertion) in mice induces chronic myelomonocytic leukemia-like disease characterized by granulomonocytosis, trilineage dysplasia, impaired HSC reconstitution activity, and myeloid lineage-biased proliferation; GATA2 hypomorphic progenitors show increased expression of CSF1R and IL6R, correlating with hypersensitive granulomonocytic proliferation.","method":"Gata2 hypomorphic mouse model (neocassette knockin), competitive transplantation, gene expression analysis of myeloid progenitors, LPS challenge experiments","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo hypomorphic mouse model with transplantation and molecular analysis; single lab","pmids":["30710465"],"is_preprint":false},{"year":2023,"finding":"Noncoding heterozygous duplications within a neuron-specific GATA2 regulatory region (including two enhancers and one silencer) or SNVs within the silencer cause hereditary congenital facial paresis (HCFP1) by extending GATA2 expression; some SNVs impair NR2F1 binding to the silencer in vitro and in vivo, attenuating enhancer reporter expression in facial branchial motor neurons; a humanized HCFP1 mouse model confirms that extended Gata2 expression favors IEE over FBMN formation, rescued by conditional loss of Gata3.","method":"Human genetic mapping, humanized HCFP1 knockin mouse model, in vitro and in vivo NR2F1 binding assays, enhancer reporter assays in FBMNs, Gata3 conditional knockout rescue","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — humanized mouse model, in vitro and in vivo binding assays, genetic rescue by Gata3 KO; multiple orthogonal methods","pmids":["37386251"],"is_preprint":false},{"year":2020,"finding":"GATA2 and progesterone receptor (PGR) co-occupy and co-regulate genes during human endometrial stromal cell decidualization; the PGR motif is highly enriched at GATA2 binding regions surrounding upregulated genes; GATA2 binding is enhanced at PGR-binding regions during decidualization, with co-regulation of WNT activation and stem cell differentiation pathways.","method":"RNA-seq, ChIP-seq (GATA2 cistrome in decidualization), integration with mined PGR ChIP-seq, pathway analysis","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq and RNA-seq integration showing co-occupancy; single lab","pmids":["32335672"],"is_preprint":false},{"year":2019,"finding":"GATA2 is required for GATA2 target gene GATA2 own transcription in the midbrain via GATA binding sites in the promoter; Gata2 promotes definitive haematopoiesis by directly binding GATA motifs within target gene regulatory regions.","method":"Referenced in context of broader auto-regulatory mechanism","journal":"IUBMB life","confidence":"Low","confidence_rationale":"Tier 4 / Weak — this is a review paper summarizing prior findings without independent experimental data; included only for completeness but confidence is low","pmids":["31675473"],"is_preprint":false},{"year":2004,"finding":"Zebrafish Pur alpha functions as a repressor and Sp8 as an activator of neural gata2 expression during embryogenesis, as demonstrated by knockdown and ectopic expression experiments.","method":"Morpholino knockdown of Pur alpha and Sp8 in zebrafish, ectopic expression, gata2 neural expression analysis","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KD and OE with defined gata2 expression phenotype in zebrafish neural tissue; single lab","pmids":["15464585"],"is_preprint":false},{"year":2021,"finding":"GATA2 regulates constitutive PD-L2 expression in brain tumors; GATA2 is sufficient to drive both PD-L1 and PD-L2 expression and is necessary for PD-L2 expression, as demonstrated by characterization of novel cis-regulatory regions in CD274 and PDCD1LG2 using luciferase assays and perturbation of GATA2.","method":"Luciferase assays with CD274/PDCD1LG2 cis-regulatory regions, GATA2 overexpression and knockdown in brain tumor cell lines and BTICs, flow cytometry for PD-L1/PD-L2","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — luciferase reporter assays with KD/OE phenotype; single lab, limited mechanistic depth","pmids":["32493985"],"is_preprint":false}],"current_model":"GATA2 is a zinc-finger transcription factor and pioneer factor that directly binds GATA DNA motifs to activate or repress target genes in a cell-type-specific manner; it undergoes cell-cycle-dependent proteasomal degradation regulated by Cdk/cyclin-mediated phosphorylation at S/T-P motifs, is phosphorylated by the MAP kinase pathway downstream of IL-3 signaling, participates in a recursive auto-regulatory and cross-regulatory circuit with Fli1 and Scl in HSCs, undergoes mitotic bookmarking via its C-terminal zinc finger to maintain definitive hematopoietic fate inheritance, regulates HSC generation specifically during endothelial-to-hematopoietic transition and is separately required for HSC survival, activates target genes including AR (in prostate cancer), NRP2 (in endothelial/lymphatic cells), miR-126 and miR-221 (in vascular biology), RASSF4 (dampening p53-mediated apoptosis), HES-1 (in myeloid progenitors), and represses GATA6 (via PRC2 recruitment) and Gata3 (in DC progenitors); its own transcription is repressed by Setd8-mediated H4K20 monomethylation and activated by STAT5 binding to the Gata2 promoter."},"narrative":{"mechanistic_narrative":"GATA2 is a zinc-finger transcription factor that orchestrates the specification, generation, and survival of hematopoietic stem cells and governs differentiation programs across hematopoietic, endothelial, and reproductive tissues by binding GATA DNA motifs to activate or repress target genes in a cell-type-specific, dosage-sensitive manner [PMID:17962413, PMID:24297996, PMID:30301799]. In hematopoietic stem cells it operates within a fully connected recursive triad with Fli1 and Scl/Tal1, in which each factor binds the others' enhancers [PMID:17962413], and it is genetically required for the endothelial-to-hematopoietic transition that generates HSCs as well as for their subsequent survival, two separable functions distinct from RUNX1 [PMID:24297996, PMID:29861167]; threshold GATA2 levels, which pulse in individual cells during this transition, set the probability of fate establishment [PMID:29217535]. GATA2 directs lineage choices by activating pro-fate targets such as HES-1 in granulocyte-macrophage progenitors [PMID:18840712] and by repressing alternative-fate genes, including Gata3 in dendritic-cell progenitors through a downstream enhancer [PMID:27259979] and GATA6 via PRC2 recruitment [PMID:29106391]. Its action is dosage- and context-dependent, integrating chromatin and enhancer logic: it increases chromatin accessibility at mast-cell super-enhancers [PMID:33479210], cooperates with PU.1 and LDB1 at composite enhancers to activate Ms4a2 [PMID:31501274], and remains bound to chromatin through mitosis via its C-terminal zinc finger to bookmark RUNX1-co-enriched targets and propagate definitive hematopoietic fate [PMID:37580379]. GATA2 protein abundance is controlled by cell-cycle-dependent, Cdk/cyclin-mediated phosphorylation at S/T-P motifs driving proteasomal degradation [PMID:17255359] and by MAP-kinase phosphorylation downstream of IL-3 [PMID:7876160], while its transcription is set by STAT5 [PMID:25801432], by autoregulation through GATA sites [PMID:19371385], and by repressive Setd8-mediated H4K20 monomethylation [PMID:25848090]. Beyond hematopoiesis, GATA2 partners with the progesterone receptor to drive uterine PGR expression and decidualization [PMID:27783953, PMID:32335672] and controls endothelial and lymphatic development through miR-126 and miR-221 [PMID:27780851, PMID:31582413]. Heterozygous zinc-finger missense mutations reduce DNA binding and transactivation, establishing GATA2 haploinsufficiency as a mechanism of MDS-AML predisposition, with some mutants additionally sequestering PU.1 and exerting non-loss-of-function effects [PMID:21892162, PMID:28642594, PMID:30301799]; GATA2 also acts as a tumor suppressor restraining PML-RARA-driven self-renewal in acute promyelocytic leukemia [PMID:34125173], and noncoding mutations that extend GATA2 expression in facial branchial motor neurons cause hereditary congenital facial paresis [PMID:37386251].","teleology":[{"year":1995,"claim":"Established that GATA2 activity is acutely regulated by signaling, linking cytokine input to transcription-factor modification rather than treating GATA2 as a static regulator.","evidence":"In vivo phosphorylation in hematopoietic progenitors, MEK mutant epistasis in COS cells, and in vitro phosphorylation of recombinant GATA2","pmids":["7876160"],"confidence":"High","gaps":["Direct MAP kinase phosphorylation site on GATA2 not definitively mapped","Functional consequence of IL-3-induced phosphorylation on target gene output unresolved"]},{"year":2006,"claim":"Placed GATA2 downstream of BMP4 and upstream of hemangioblast/endothelial programs, defining its role in early blood/vessel fate commitment.","evidence":"ES cell differentiation with conditional GATA2 induction and BMP4 stimulation","pmids":["17166922"],"confidence":"Medium","gaps":["Direct GATA2 occupancy at Bmp4/Flk1/Scl loci not shown here","Temporal-window dependence not mechanistically explained"]},{"year":2007,"claim":"Showed GATA2 abundance oscillates with the cell cycle via Cdk/cyclin phosphorylation and proteasomal turnover, revealing post-translational control of a master hematopoietic factor.","evidence":"Cell-cycle synchronization, Co-IP with Cdk2/cyclinA2 and Cdk4/cyclinD1, in vitro Cdk phosphorylation, site mutagenesis, proteasome inhibition","pmids":["17255359"],"confidence":"High","gaps":["E3 ligase mediating GATA2 degradation not identified","Functional output of cell-cycle-phased GATA2 levels on target genes unresolved"]},{"year":2007,"claim":"Defined the Gata2-Fli1-Scl recursive triad, providing the architecture for how HSC identity is stably maintained through mutual cross-activation.","evidence":"Reciprocal ChIP at three HSC enhancers across embryonic and ES-derived contexts with transgenic reporters","pmids":["17962413"],"confidence":"High","gaps":["Quantitative contribution of each triad edge to HSC maintenance not dissected","Dynamics of circuit establishment during EHT not addressed"]},{"year":2008,"claim":"Identified HES-1 as a functional GATA2 target whose restoration rescues haploinsufficient progenitor defects, providing a concrete effector for GATA2 dosage phenotypes.","evidence":"GATA2+/- mice, ChIP at HES-1 locus, RNAi, colony/transplantation assays, HES-1 forced-expression rescue","pmids":["18840712"],"confidence":"High","gaps":["Whether HES-1 accounts for all GMP defects unclear","Direct binding site within HES-1 locus not finely mapped"]},{"year":2009,"claim":"Demonstrated direct GATA2 positive autoregulation through defined promoter GATA sites in a non-hematopoietic (midbrain) context, generalizing self-reinforcement of GATA2 expression.","evidence":"Transgenic reporter mice with promoter-domain deletion and Gata2/Gata3 KO epistasis","pmids":["19371385"],"confidence":"Medium","gaps":["Whether the same promoter domains drive hematopoietic autoregulation untested here","Single-lab in vivo reporter system"]},{"year":2011,"claim":"Established GATA2 haploinsufficiency as a mechanism of MDS-AML predisposition by showing founding zinc-finger mutations reduce DNA binding and transactivation.","evidence":"Transactivation, differentiation, apoptosis, and gene expression assays on patient-derived ZF2 mutations","pmids":["21892162"],"confidence":"High","gaps":["In vivo leukemogenic mechanism not modeled in this study","Cell-of-origin and second-hit requirements unaddressed"]},{"year":2013,"claim":"Genetically separated GATA2's role in HSC generation during EHT from its requirement in HSC survival, refining when and where GATA2 acts and distinguishing it from RUNX1.","evidence":"Vec-Cre and Vav-Cre conditional Gata2 deletion with LT-repopulation and aortic cluster analysis","pmids":["24297996"],"confidence":"High","gaps":["Survival-stage target genes not defined","Molecular distinction from RUNX1 at the target level unresolved"]},{"year":2013,"claim":"Extended GATA2 function beyond hematopoiesis by showing it forms complexes with LMO2 to activate NRP2 and drive angiogenesis/lymphangiogenesis.","evidence":"siRNA/overexpression, sprouting assays, NRP2 promoter analysis and rescue in endothelial cells","pmids":["23892628"],"confidence":"Medium","gaps":["Direct GATA2-LMO2 physical interaction not biochemically resolved here","Partial NRP2 rescue implies additional effectors"]},{"year":2013,"claim":"Revealed GATA2 as a context-dependent repressor recruiting PRC2 to silence GATA6, expanding its mechanistic repertoire to Polycomb-mediated repression.","evidence":"ChIP for GATA2 and PRC2 at GATA6 locus with KD/OE and bisulfite analysis in gastric cancer cells","pmids":["29106391"],"confidence":"Medium","gaps":["Direct GATA2-PRC2 contact not demonstrated","Single cancer-cell context"]},{"year":2014,"claim":"Identified GATA2 as a driver of androgen receptor expression and a chromatin co-factor with AR/FOXA1 in prostate cancer, defining an oncogenic transcriptional role.","evidence":"ChIP co-occupancy, Co-IP, coactivator recruitment, KD/OE in prostate cancer cells with patient correlation","pmids":["25489091"],"confidence":"High","gaps":["Direct vs. indirect coactivator bridging not separated","Generalizability beyond prostate lineage untested"]},{"year":2014,"claim":"Showed GATA2 physically partners with Etv2 via GATA/Ets domains to co-activate shared endothelial/hematopoietic targets, providing a protein-level cooperativity mechanism.","evidence":"Reciprocal Co-IP, domain-mapping, embryoid-body differentiation, ChIP at Spi1 promoter","pmids":["24583263"],"confidence":"Medium","gaps":["Genome-wide co-occupancy not assessed","Functional necessity of the interaction in vivo not tested"]},{"year":2015,"claim":"Placed GATA2 downstream of STAT5 as a direct transcriptional target sufficient to drive basophil/mast-cell fate, connecting cytokine signaling to GATA2-driven differentiation.","evidence":"STAT5 ChIP at Gata2 locus and Gata2 overexpression rescue in Stat5-deficient cells","pmids":["25801432"],"confidence":"High","gaps":["Other STAT5-independent inputs to Gata2 not delineated","Lineage breadth of this pathway beyond basophil/mast cell unclear"]},{"year":2015,"claim":"Defined repressive epigenetic control of the Gata2 locus by Setd8/H4K20me1 during erythroid maturation, showing Gata2 silencing is required for differentiation.","evidence":"Setd8 knockdown, ChIP for occupancy and histone marks at Gata2 locus, Gata2 KD rescue in erythroblasts","pmids":["25848090"],"confidence":"High","gaps":["How Setd8 is targeted to the Gata2 locus unknown","Whether this mechanism operates in HSCs untested"]},{"year":2016,"claim":"Established GATA2 as a uterine regulator activating PGR and progesterone signaling, defining a reproductive function essential for implantation and decidualization.","evidence":"Uterine conditional Gata2 KO with ChIP-seq at Pgr and RNA-seq, implantation/decidualization phenotyping","pmids":["27783953"],"confidence":"High","gaps":["Upstream regulators of uterine GATA2 not defined","GATA2-PGR physical interaction not addressed here"]},{"year":2016,"claim":"Showed GATA2 controls vascular integrity through opposing regulation of miR-126 and miR-221, including DNA-methylation-mediated silencing, broadening its endothelial effector network.","evidence":"Endothelial KD/OE, ChIP, luciferase, bisulfite sequencing, and in vivo carotid-injury miR-126 rescue","pmids":["27780851"],"confidence":"High","gaps":["Mechanism by which GATA2 directs miR-221 promoter methylation unclear","Relative contribution of each miRNA arm in vivo not partitioned"]},{"year":2016,"claim":"Demonstrated GATA2 represses Gata3 via a long-range enhancer to enforce myeloid over lymphoid identity in dendritic-cell progenitors.","evidence":"Conditional/haploinsufficient mice, in vitro DC generation, reporter assays with GATA-site mutagenesis at Gata3 +190","pmids":["27259979"],"confidence":"High","gaps":["Co-repressors mediating Gata3 silencing not identified","Direct vs. indirect myeloid gene activation not fully separated"]},{"year":2017,"claim":"Refined the GATA2 mutation model by showing ZF2 mutants not only lose DNA binding but can gain PU.1 sequestration, indicating effects beyond simple haploinsufficiency.","evidence":"DNA-binding, transactivation, Co-IP with PU.1, colony and cell-fate assays on multiple mutants","pmids":["28642594"],"confidence":"High","gaps":["In vivo relevance of enhanced PU.1 binding untested","Allele-specific clinical correlation not established"]},{"year":2017,"claim":"Showed GATA2 is required for AR-driven SEMA3C activation, reinforcing its role as an obligate co-factor in androgen-responsive transcription.","evidence":"ChIP for GATA2/AR at SEMA3C, GATA2 KD, androgen stimulation, luciferase assays in LNCaP","pmids":["28038451"],"confidence":"Medium","gaps":["Mechanism of FOXA1 antagonism not resolved","Single-cell-line context"]},{"year":2018,"claim":"Demonstrated that disease-associated N-finger mutations reduce chromatin occupancy yet can promote myeloid differentiation, showing GATA2 pathogenesis is not strictly loss-of-function.","evidence":"Genetic complementation in -77 enhancer-mutant myeloid progenitors with occupancy and differentiation readouts","pmids":["30301799"],"confidence":"High","gaps":["Mechanism of myeloid-promoting gain-of-function unclear","Relationship to leukemic transformation not directly tested"]},{"year":2019,"claim":"Dissected enhancer-specific functions, showing the +9.5 Ets motif is dispensable for steady-state but essential for stress regeneration, separating developmental from regenerative GATA2 activity.","evidence":"Mouse knockin of +9.5 Ets-motif mutations with steady-state vs. stress hematopoiesis assays","pmids":["30620726"],"confidence":"High","gaps":["Stress-specific transcription factors acting at +9.5 not identified","Molecular basis of regeneration-selective requirement unresolved"]},{"year":2019,"claim":"Defined composite enhancer logic in mast cells, showing GATA2 and PU.1 cooperate with LDB1 at a downstream enhancer essential for Ms4a2, with PU.1 supporting GATA2 binding.","evidence":"ChIP-seq, siRNA, genome-editing deletion of +10.4-kbp enhancer, chromatin looping","pmids":["31501274"],"confidence":"High","gaps":["Hierarchy of GATA2/PU.1/LDB1 assembly not fully ordered","Generality across mast-cell genes untested"]},{"year":2019,"claim":"Showed GATA2 governs lymphatic valve morphogenesis through miR-126 control of junctional molecules, linking GATA2 to endothelial barrier architecture.","evidence":"Conditional GATA2 KO mouse and HLEC siRNA with miR-126 overexpression rescue and junction immunostaining","pmids":["31582413"],"confidence":"High","gaps":["Direct GATA2 occupancy at junction genes vs. miR-126-mediated effect not fully separated","Valve-specific co-factors unidentified"]},{"year":2019,"claim":"Modeled GATA2 hypomorphism as causing CMML-like disease with myeloid bias and cytokine-receptor upregulation, connecting reduced dosage to specific malignant phenotypes.","evidence":"Gata2 hypomorphic neocassette mice with transplantation, expression analysis, LPS challenge","pmids":["30710465"],"confidence":"Medium","gaps":["Direct GATA2 regulation of CSF1R/IL6R not demonstrated","Single-lab model"]},{"year":2019,"claim":"Pinpointed the precise developmental window of GATA2 requirement to the EHT step of hemogenic endothelium, showing it is dispensable for HE specification and diversification.","evidence":"GATA2 KO hESC lines with conditional/forced expression and hematopoietic differentiation assays","pmids":["29861167"],"confidence":"High","gaps":["Targets executing the EHT step not catalogued","Why forced GATA2 cannot reprogram non-HE unexplained"]},{"year":2020,"claim":"Used multiomics to show the -77 enhancer coordinates both pro-fate and innate-immunity anti-fate circuits, reframing GATA2 dosage as balancing opposing programs in single progenitors.","evidence":"Murine -77 enhancer deletion with single-cell multiomics and differentiation assays","pmids":["32736380"],"confidence":"High","gaps":["Identity of the fate-suppressing innate immunity effectors incomplete","Mechanism linking GATA2 level to immunity program off-switch unresolved"]},{"year":2020,"claim":"Showed conserved enhancer-driven Gata2 autoactivation in zebrafish hemogenic endothelium feeds into runx1 and Notch circuitry, generalizing GATA2 positive autoregulation in blood development.","evidence":"CRISPR i4 enhancer deletion with downstream runx1/gata2b expression and Notch analysis","pmids":["32054973"],"confidence":"Medium","gaps":["Direct GATA2 binding at i4 not shown here","Mapping to mammalian enhancers uncertain"]},{"year":2020,"claim":"Established genome-wide GATA2-PGR co-occupancy as the basis of decidualization gene regulation, deepening the GATA2 reproductive mechanism.","evidence":"GATA2 ChIP-seq and RNA-seq integrated with PGR ChIP-seq in human endometrial stromal cells","pmids":["32335672"],"confidence":"Medium","gaps":["Direct GATA2-PGR physical interaction not tested","Causality of co-binding vs. sequential binding unresolved"]},{"year":2021,"claim":"Showed GATA2 establishes chromatin accessibility at mast-cell super-enhancers and primes antigen-responsive loci, framing it as a determinant of enhancer landscape and identity.","evidence":"GATA2 KO mast cells with ATAC-seq, ChIP-seq, and RNA-seq","pmids":["33479210"],"confidence":"High","gaps":["Whether GATA2 acts as a pioneer factor at these sites not directly demonstrated","Order relative to other identity factors unresolved"]},{"year":2021,"claim":"Defined GATA2 as a tumor suppressor restraining PML-RARA-driven self-renewal, with the R362G allele confirmed as loss-of-function in APL.","evidence":"CRISPR biallelic Gata2 KO, serial replating, mouse leukemia penetrance/latency, WT and mutant addback","pmids":["34125173"],"confidence":"High","gaps":["Target genes mediating self-renewal suppression not identified","Interaction with PML-RARA at chromatin not characterized"]},{"year":2022,"claim":"Placed GATA2 downstream of HMGA1 as a target whose re-expression partially rescues leukemogenesis, linking it to a chromatin-accessibility regulatory axis in MPN.","evidence":"CRISPR/shRNA, RNA-seq, HMGA1 ChIP-seq at +9.5 GATA2 enhancer, accessibility assays, GATA2 rescue","pmids":["35286385"],"confidence":"High","gaps":["Why GATA2 re-expression only partially rescues unresolved","Context-dependence (tumor-suppressor vs. oncogenic) of GATA2 in myeloid disease not reconciled"]},{"year":2023,"claim":"Demonstrated GATA2 mitotic bookmarking via the C-terminal zinc finger maintains definitive hematopoietic fate, providing a mechanism for heritable transcriptional memory through cell division.","evidence":"Live imaging, GATA2-cyclinB1 degron knockin mouse, mitotic vs. interphase ChIP, ZF domain deletion, multiomics","pmids":["37580379"],"confidence":"High","gaps":["How bookmarked targets are reactivated post-mitosis not detailed","Functional role of RUNX1 co-enrichment at bookmarked sites untested"]},{"year":2023,"claim":"Linked noncoding GATA2 regulatory mutations that extend its expression in facial motor neurons to hereditary congenital facial paresis, establishing a gain-of-expression neurodevelopmental disease mechanism.","evidence":"Human genetic mapping, humanized HCFP1 mouse, NR2F1 binding assays, FBMN reporter assays, Gata3 KO rescue","pmids":["37386251"],"confidence":"High","gaps":["Full set of GATA2 targets driving FBMN-to-IEE fate shift unresolved","Generalizability of silencer/enhancer logic to other GATA2-dependent tissues unclear"]},{"year":2025,"claim":"Identified RASSF4 as a GATA2 target that dampens p53-mediated apoptosis, providing a mechanism by which GATA2 levels modulate chemoresistance in AML.","evidence":"ChIP-seq, RNA-seq, CRISPR GATA2 deletion, Rassf4 KD/OE, doxorubicin and nutlin-3 assays, patient data","pmids":["39841459"],"confidence":"High","gaps":["Direct RASSF4-MDM2-p53 biochemical link not shown here","Therapeutic exploitability across GATA2-mutant subtypes untested"]},{"year":null,"claim":"How GATA2 dosage and the same DNA-binding activity are reconciled across opposing roles — pro-fate activator vs. anti-fate repressor, tumor suppressor vs. oncogenic AR co-factor — remains unresolved at the level of context-defining co-factors and chromatin state.","evidence":"No single study reconciles the divergent context-dependent outputs","pmids":[],"confidence":"Low","gaps":["No unified model linking GATA2 partner identity to activator vs. repressor output","E3 ligase and full post-translational control network incomplete","Determinants of tissue-specific enhancer selection not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,3,5,13,23,28]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,16,17,25]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,25]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[25,23]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,3,5,13,23,28]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[4,6,33,30]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,34,36]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[12,23,25,28]}],"complexes":["PRC2 (recruited by GATA2 at GATA6 locus)","Gata2-Fli1-Scl HSC triad"],"partners":["FLI1","TAL1","PU.1","LMO2","ETV2","PGR","FOXA1","AR"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P23769","full_name":"Endothelial transcription factor GATA-2","aliases":["GATA-binding protein 2"],"length_aa":480,"mass_kda":50.5,"function":"Transcriptional activator which regulates endothelin-1 gene expression in endothelial cells. Binds to the consensus sequence 5'-AGATAG-3'","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P23769/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GATA2","classification":"Not Classified","n_dependent_lines":27,"n_total_lines":1208,"dependency_fraction":0.022350993377483443},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GATA2","total_profiled":1310},"omim":[{"mim_id":"621229","title":"GATA2 ANTISENSE RNA 1, NONCODING; GATA2AS1","url":"https://www.omim.org/entry/621229"},{"mim_id":"619233","title":"STERILE ALPHA MOTIF DOMAIN-CONTAINING PROTEIN 14; SAMD14","url":"https://www.omim.org/entry/619233"},{"mim_id":"617138","title":"SKI FAMILY TRANSCRIPTIONAL COREPRESSOR 2; SKOR2","url":"https://www.omim.org/entry/617138"},{"mim_id":"614511","title":"MYOD FAMILY INHIBITOR DOMAIN-CONTAINING PROTEIN; MDFIC","url":"https://www.omim.org/entry/614511"},{"mim_id":"614286","title":"MYELODYSPLASTIC SYNDROME; MDS","url":"https://www.omim.org/entry/614286"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/GATA2"},"hgnc":{"alias_symbol":["NFE1B"],"prev_symbol":[]},"alphafold":{"accession":"P23769","domains":[{"cath_id":"3.30.50.10","chopping":"290-339","consensus_level":"medium","plddt":87.4972,"start":290,"end":339},{"cath_id":"3.30.50.10","chopping":"340-392","consensus_level":"medium","plddt":91.8791,"start":340,"end":392}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P23769","model_url":"https://alphafold.ebi.ac.uk/files/AF-P23769-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P23769-F1-predicted_aligned_error_v6.png","plddt_mean":56.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GATA2","jax_strain_url":"https://www.jax.org/strain/search?query=GATA2"},"sequence":{"accession":"P23769","fasta_url":"https://rest.uniprot.org/uniprotkb/P23769.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P23769/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P23769"}},"corpus_meta":[{"pmid":"21892162","id":"PMC_21892162","title":"Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.","date":"2011","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21892162","citation_count":471,"is_preprint":false},{"pmid":"25707267","id":"PMC_25707267","title":"Haematopoietic and immune defects associated with GATA2 mutation.","date":"2015","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/25707267","citation_count":198,"is_preprint":false},{"pmid":"24297996","id":"PMC_24297996","title":"Gata2 is required for HSC generation and survival.","date":"2013","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24297996","citation_count":197,"is_preprint":false},{"pmid":"17962413","id":"PMC_17962413","title":"Gata2, Fli1, and Scl form a recursively wired gene-regulatory circuit during early hematopoietic development.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17962413","citation_count":184,"is_preprint":false},{"pmid":"24345756","id":"PMC_24345756","title":"The evolution of cellular deficiency in GATA2 mutation.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/24345756","citation_count":175,"is_preprint":false},{"pmid":"17166922","id":"PMC_17166922","title":"GATA2 functions at multiple steps in hemangioblast development and differentiation.","date":"2006","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/17166922","citation_count":139,"is_preprint":false},{"pmid":"21605981","id":"PMC_21605981","title":"The role of the GATA2 transcription factor in normal and malignant hematopoiesis.","date":"2011","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/21605981","citation_count":138,"is_preprint":false},{"pmid":"16543408","id":"PMC_16543408","title":"Pituitary-specific Gata2 knockout: effects on gonadotrope and thyrotrope function.","date":"2006","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/16543408","citation_count":133,"is_preprint":false},{"pmid":"28637621","id":"PMC_28637621","title":"GATA2 deficiency and related myeloid neoplasms.","date":"2017","source":"Seminars in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/28637621","citation_count":124,"is_preprint":false},{"pmid":"22996665","id":"PMC_22996665","title":"Conditional Gata2 inactivation results in HSC loss and lymphatic mispatterning.","date":"2012","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/22996665","citation_count":124,"is_preprint":false},{"pmid":"7738198","id":"PMC_7738198","title":"Differential expression and functional role of GATA-2, NF-E2, and GATA-1 in normal adult hematopoiesis.","date":"1995","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/7738198","citation_count":113,"is_preprint":false},{"pmid":"25397911","id":"PMC_25397911","title":"GATA2 deficiency.","date":"2015","source":"Current opinion in allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25397911","citation_count":107,"is_preprint":false},{"pmid":"25489091","id":"PMC_25489091","title":"GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25489091","citation_count":101,"is_preprint":false},{"pmid":"7876160","id":"PMC_7876160","title":"Regulation of GATA-2 phosphorylation by mitogen-activated protein kinase and interleukin-3.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7876160","citation_count":101,"is_preprint":false},{"pmid":"25801432","id":"PMC_25801432","title":"The STAT5-GATA2 pathway is critical in basophil and mast cell differentiation and maintenance.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25801432","citation_count":95,"is_preprint":false},{"pmid":"24638828","id":"PMC_24638828","title":"A regulatory network governing Gata1 and Gata2 gene transcription orchestrates erythroid lineage differentiation.","date":"2014","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/24638828","citation_count":83,"is_preprint":false},{"pmid":"18840712","id":"PMC_18840712","title":"GATA-2 regulates granulocyte-macrophage progenitor cell function.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18840712","citation_count":79,"is_preprint":false},{"pmid":"27872477","id":"PMC_27872477","title":"The role of GATA2 in lethal prostate cancer aggressiveness.","date":"2016","source":"Nature reviews. Urology","url":"https://pubmed.ncbi.nlm.nih.gov/27872477","citation_count":78,"is_preprint":false},{"pmid":"32430494","id":"PMC_32430494","title":"Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).","date":"2020","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/32430494","citation_count":74,"is_preprint":false},{"pmid":"36455197","id":"PMC_36455197","title":"The spectrum of GATA2 deficiency syndrome.","date":"2023","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/36455197","citation_count":72,"is_preprint":false},{"pmid":"27783953","id":"PMC_27783953","title":"A Gata2-Dependent Transcription Network Regulates Uterine Progesterone Responsiveness and Endometrial Function.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27783953","citation_count":71,"is_preprint":false},{"pmid":"19136559","id":"PMC_19136559","title":"Re-expression of GATA2 cooperates with peroxisome proliferator-activated receptor-gamma depletion to revert the adipocyte phenotype.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19136559","citation_count":65,"is_preprint":false},{"pmid":"32960960","id":"PMC_32960960","title":"Human GATA2 mutations and hematologic disease: how many paths to pathogenesis?","date":"2020","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/32960960","citation_count":63,"is_preprint":false},{"pmid":"30047422","id":"PMC_30047422","title":"Germline GATA2 Mutation and Bone Marrow Failure.","date":"2018","source":"Hematology/oncology clinics of North America","url":"https://pubmed.ncbi.nlm.nih.gov/30047422","citation_count":62,"is_preprint":false},{"pmid":"24448395","id":"PMC_24448395","title":"GATA2 as a potential metastasis-driving gene in prostate cancer.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24448395","citation_count":54,"is_preprint":false},{"pmid":"26264606","id":"PMC_26264606","title":"GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders.","date":"2015","source":"BMC pulmonary medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26264606","citation_count":54,"is_preprint":false},{"pmid":"28642594","id":"PMC_28642594","title":"Differential effects on gene transcription and hematopoietic differentiation correlate with GATA2 mutant disease phenotypes.","date":"2017","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/28642594","citation_count":53,"is_preprint":false},{"pmid":"15499560","id":"PMC_15499560","title":"Partially overlapping expression of Gata2 and Gata3 during inner ear development.","date":"2004","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/15499560","citation_count":51,"is_preprint":false},{"pmid":"24583263","id":"PMC_24583263","title":"Cooperative interaction of Etv2 and Gata2 regulates the development of endothelial and hematopoietic lineages.","date":"2014","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/24583263","citation_count":51,"is_preprint":false},{"pmid":"30620726","id":"PMC_30620726","title":"Single-nucleotide human disease mutation inactivates a blood-regenerative GATA2 enhancer.","date":"2019","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/30620726","citation_count":50,"is_preprint":false},{"pmid":"27780851","id":"PMC_27780851","title":"MicroRNA-Based Therapy of GATA2-Deficient Vascular Disease.","date":"2016","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/27780851","citation_count":49,"is_preprint":false},{"pmid":"27259979","id":"PMC_27259979","title":"GATA2 regulates dendritic cell differentiation.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/27259979","citation_count":47,"is_preprint":false},{"pmid":"34387894","id":"PMC_34387894","title":"GATA2 deficiency syndrome: A decade of discovery.","date":"2021","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/34387894","citation_count":47,"is_preprint":false},{"pmid":"23892628","id":"PMC_23892628","title":"GATA2 and Lmo2 control angiogenesis and lymphangiogenesis via direct transcriptional regulation of neuropilin-2.","date":"2013","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/23892628","citation_count":47,"is_preprint":false},{"pmid":"33479210","id":"PMC_33479210","title":"GATA2 regulates mast cell identity and responsiveness to antigenic stimulation by promoting chromatin remodeling at super-enhancers.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33479210","citation_count":44,"is_preprint":false},{"pmid":"34529785","id":"PMC_34529785","title":"ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome.","date":"2022","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/34529785","citation_count":44,"is_preprint":false},{"pmid":"28643018","id":"PMC_28643018","title":"Heterogeneity of GATA2-related myeloid neoplasms.","date":"2017","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/28643018","citation_count":43,"is_preprint":false},{"pmid":"28630119","id":"PMC_28630119","title":"GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28630119","citation_count":41,"is_preprint":false},{"pmid":"30301799","id":"PMC_30301799","title":"Human leukemia mutations corrupt but do not abrogate GATA-2 function.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30301799","citation_count":41,"is_preprint":false},{"pmid":"31582413","id":"PMC_31582413","title":"GATA2 controls lymphatic endothelial cell junctional integrity and lymphovenous valve morphogenesis through miR-126.","date":"2019","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/31582413","citation_count":40,"is_preprint":false},{"pmid":"29861167","id":"PMC_29861167","title":"GATA2 Is Dispensable for Specification of Hemogenic Endothelium but Promotes Endothelial-to-Hematopoietic Transition.","date":"2018","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29861167","citation_count":40,"is_preprint":false},{"pmid":"34089740","id":"PMC_34089740","title":"Pulmonary Manifestations of GATA2 Deficiency.","date":"2021","source":"Chest","url":"https://pubmed.ncbi.nlm.nih.gov/34089740","citation_count":39,"is_preprint":false},{"pmid":"32736380","id":"PMC_32736380","title":"Constructing and deconstructing GATA2-regulated cell fate programs to establish developmental trajectories.","date":"2020","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32736380","citation_count":39,"is_preprint":false},{"pmid":"35289315","id":"PMC_35289315","title":"A CGA/EGFR/GATA2 positive feedback circuit confers chemoresistance in gastric cancer.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/35289315","citation_count":39,"is_preprint":false},{"pmid":"37406166","id":"PMC_37406166","title":"Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41.","date":"2023","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/37406166","citation_count":38,"is_preprint":false},{"pmid":"30578959","id":"PMC_30578959","title":"MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations.","date":"2018","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/30578959","citation_count":38,"is_preprint":false},{"pmid":"33417088","id":"PMC_33417088","title":"Inherited GATA2 Deficiency Is Dominant by Haploinsufficiency and Displays Incomplete Clinical Penetrance.","date":"2021","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33417088","citation_count":36,"is_preprint":false},{"pmid":"29217535","id":"PMC_29217535","title":"In vivo single cell analysis reveals Gata2 dynamics in cells transitioning to hematopoietic fate.","date":"2017","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29217535","citation_count":36,"is_preprint":false},{"pmid":"24514424","id":"PMC_24514424","title":"Epigenetic regulation of GATA2 and its impact on normal karyotype acute myeloid leukemia.","date":"2014","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/24514424","citation_count":36,"is_preprint":false},{"pmid":"35286385","id":"PMC_35286385","title":"HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/35286385","citation_count":33,"is_preprint":false},{"pmid":"34244664","id":"PMC_34244664","title":"Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome.","date":"2021","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/34244664","citation_count":33,"is_preprint":false},{"pmid":"26834239","id":"PMC_26834239","title":"Functional and molecular characterization of mouse Gata2-independent hematopoietic progenitors.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/26834239","citation_count":32,"is_preprint":false},{"pmid":"28440875","id":"PMC_28440875","title":"Skin manifestations among GATA2-deficient patients.","date":"2017","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/28440875","citation_count":30,"is_preprint":false},{"pmid":"36416237","id":"PMC_36416237","title":"NONO enhances mRNA processing of super-enhancer-associated GATA2 and HAND2 genes in neuroblastoma.","date":"2022","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/36416237","citation_count":30,"is_preprint":false},{"pmid":"30538114","id":"PMC_30538114","title":"GATA2 deficiency and human hematopoietic development modeled using induced pluripotent stem cells.","date":"2018","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/30538114","citation_count":30,"is_preprint":false},{"pmid":"29106391","id":"PMC_29106391","title":"Aberrant GATA2 epigenetic dysregulation induces a GATA2/GATA6 switch in human gastric cancer.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29106391","citation_count":30,"is_preprint":false},{"pmid":"36727400","id":"PMC_36727400","title":"Somatic genetic alterations predict hematological progression in GATA2 deficiency.","date":"2023","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/36727400","citation_count":29,"is_preprint":false},{"pmid":"38033856","id":"PMC_38033856","title":"The role of GATA2 in adult hematopoiesis and cell fate determination.","date":"2023","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/38033856","citation_count":29,"is_preprint":false},{"pmid":"31289032","id":"PMC_31289032","title":"Blood disease-causing and -suppressing transcriptional enhancers: general principles and GATA2 mechanisms.","date":"2019","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/31289032","citation_count":29,"is_preprint":false},{"pmid":"21279818","id":"PMC_21279818","title":"Transcriptional regulation by GATA1 and GATA2 during erythropoiesis.","date":"2011","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/21279818","citation_count":29,"is_preprint":false},{"pmid":"37386251","id":"PMC_37386251","title":"Noncoding variants alter GATA2 expression in rhombomere 4 motor neurons and cause dominant hereditary congenital facial paresis.","date":"2023","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37386251","citation_count":28,"is_preprint":false},{"pmid":"31402335","id":"PMC_31402335","title":"GATA2 Promotes Hematopoietic Development and Represses Cardiac Differentiation of Human Mesoderm.","date":"2019","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31402335","citation_count":28,"is_preprint":false},{"pmid":"35753998","id":"PMC_35753998","title":"GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects.","date":"2022","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/35753998","citation_count":27,"is_preprint":false},{"pmid":"32054973","id":"PMC_32054973","title":"Deletion of a conserved Gata2 enhancer impairs haemogenic endothelium programming and adult Zebrafish haematopoiesis.","date":"2020","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/32054973","citation_count":27,"is_preprint":false},{"pmid":"17255359","id":"PMC_17255359","title":"Cell-cycle-dependent oscillation of GATA2 expression in hematopoietic cells.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17255359","citation_count":26,"is_preprint":false},{"pmid":"34125173","id":"PMC_34125173","title":"Tumor suppressor function of Gata2 in acute promyelocytic leukemia.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34125173","citation_count":26,"is_preprint":false},{"pmid":"25848090","id":"PMC_25848090","title":"Histone methyltransferase Setd8 represses Gata2 expression and regulates erythroid maturation.","date":"2015","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25848090","citation_count":25,"is_preprint":false},{"pmid":"32770553","id":"PMC_32770553","title":"Prevalence of germline GATA2 and SAMD9/9L variants in paediatric haematological disorders with monosomy 7.","date":"2020","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/32770553","citation_count":25,"is_preprint":false},{"pmid":"33831168","id":"PMC_33831168","title":"Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33831168","citation_count":24,"is_preprint":false},{"pmid":"15464585","id":"PMC_15464585","title":"Pur alpha and Sp8 as opposing regulators of neural gata2 expression.","date":"2004","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/15464585","citation_count":24,"is_preprint":false},{"pmid":"33066218","id":"PMC_33066218","title":"GATA2 Related Conditions and Predisposition to Pediatric Myelodysplastic Syndromes.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33066218","citation_count":23,"is_preprint":false},{"pmid":"30044048","id":"PMC_30044048","title":"NR4A1 retards adipocyte differentiation or maturation via enhancing GATA2 and p53 expression.","date":"2018","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30044048","citation_count":23,"is_preprint":false},{"pmid":"25707769","id":"PMC_25707769","title":"GATA2 promotes glioma progression through EGFR/ERK/Elk-1 pathway.","date":"2015","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25707769","citation_count":23,"is_preprint":false},{"pmid":"31710708","id":"PMC_31710708","title":"GATA2 deficiency and haematopoietic stem cell transplantation: challenges for the clinical practitioner.","date":"2019","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/31710708","citation_count":22,"is_preprint":false},{"pmid":"32493985","id":"PMC_32493985","title":"GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32493985","citation_count":21,"is_preprint":false},{"pmid":"32330245","id":"PMC_32330245","title":"EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis.","date":"2020","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/32330245","citation_count":21,"is_preprint":false},{"pmid":"34170284","id":"PMC_34170284","title":"Single-cell ATAC-seq reveals GATA2-dependent priming defect in myeloid and a maturation bottleneck in lymphoid lineages.","date":"2021","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/34170284","citation_count":21,"is_preprint":false},{"pmid":"29375553","id":"PMC_29375553","title":"GATA2 Deficiency and Epstein-Barr Virus Disease.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29375553","citation_count":20,"is_preprint":false},{"pmid":"35538035","id":"PMC_35538035","title":"LINC00891 regulated by miR-128-3p/GATA2 axis impedes lung cancer cell proliferation, invasion and EMT by inhibiting RhoA pathway.","date":"2022","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/35538035","citation_count":20,"is_preprint":false},{"pmid":"37624387","id":"PMC_37624387","title":"Role of the pioneer transcription factor GATA2 in health and disease.","date":"2023","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/37624387","citation_count":18,"is_preprint":false},{"pmid":"35752837","id":"PMC_35752837","title":"A feedback loop between GATA2-AS1 and GATA2 promotes colorectal cancer cell proliferation, invasion, epithelial-mesenchymal transition and stemness via recruiting DDX3X.","date":"2022","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35752837","citation_count":18,"is_preprint":false},{"pmid":"32335672","id":"PMC_32335672","title":"GATA2 and Progesterone Receptor Interaction in Endometrial Stromal Cells Undergoing Decidualization.","date":"2020","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32335672","citation_count":17,"is_preprint":false},{"pmid":"23592430","id":"PMC_23592430","title":"Control of endothelin-a receptor expression by progesterone is enhanced by synergy with Gata2.","date":"2013","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/23592430","citation_count":17,"is_preprint":false},{"pmid":"31675473","id":"PMC_31675473","title":"Quantitative and qualitative impairments in GATA2 and myeloid neoplasms.","date":"2019","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/31675473","citation_count":16,"is_preprint":false},{"pmid":"37507762","id":"PMC_37507762","title":"A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer.","date":"2023","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/37507762","citation_count":16,"is_preprint":false},{"pmid":"19371385","id":"PMC_19371385","title":"GATA2-dependent and region-specific regulation of Gata2 transcription in the mouse midbrain.","date":"2009","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/19371385","citation_count":16,"is_preprint":false},{"pmid":"28038451","id":"PMC_28038451","title":"Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28038451","citation_count":16,"is_preprint":false},{"pmid":"31607132","id":"PMC_31607132","title":"A MYC target long non-coding RNA GATA2-AS1 regulates non-small cell lung cancer growth.","date":"2019","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/31607132","citation_count":16,"is_preprint":false},{"pmid":"34471858","id":"PMC_34471858","title":"Gata2 heterozygous mutant mice exhibit reduced inflammatory responses and impaired bacterial clearance.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/34471858","citation_count":16,"is_preprint":false},{"pmid":"36900380","id":"PMC_36900380","title":"The Clinical Spectrum, Diagnosis, and Management of GATA2 Deficiency.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36900380","citation_count":15,"is_preprint":false},{"pmid":"32433473","id":"PMC_32433473","title":"A Panoply of Rheumatological Manifestations in Patients with GATA2 Deficiency.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32433473","citation_count":15,"is_preprint":false},{"pmid":"31501274","id":"PMC_31501274","title":"GATA2 and PU.1 Collaborate To Activate the Expression of the Mouse Ms4a2 Gene, Encoding FcεRIβ, through Distinct Mechanisms.","date":"2019","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/31501274","citation_count":15,"is_preprint":false},{"pmid":"31785092","id":"PMC_31785092","title":"GATA2 mutations in myeloid malignancies: Two zinc fingers in many pies.","date":"2019","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/31785092","citation_count":14,"is_preprint":false},{"pmid":"37580379","id":"PMC_37580379","title":"GATA2 mitotic bookmarking is required for definitive haematopoiesis.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37580379","citation_count":14,"is_preprint":false},{"pmid":"30710465","id":"PMC_30710465","title":"GATA2 hypomorphism induces chronic myelomonocytic leukemia in mice.","date":"2019","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/30710465","citation_count":14,"is_preprint":false},{"pmid":"34893945","id":"PMC_34893945","title":"A Nationwide Study of GATA2 Deficiency in Norway-the Majority of Patients Have Undergone Allo-HSCT.","date":"2021","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34893945","citation_count":14,"is_preprint":false},{"pmid":"39841459","id":"PMC_39841459","title":"GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia.","date":"2025","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/39841459","citation_count":13,"is_preprint":false},{"pmid":"34636746","id":"PMC_34636746","title":"Inhibition of GATA2 in prostate cancer by a clinically available small molecule.","date":"2021","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34636746","citation_count":13,"is_preprint":false},{"pmid":"28114350","id":"PMC_28114350","title":"GATA2 Inhibition Sensitizes Acute Myeloid Leukemia Cells to Chemotherapy.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28114350","citation_count":13,"is_preprint":false},{"pmid":"37794021","id":"PMC_37794021","title":"TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37794021","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49249,"output_tokens":11208,"usd":0.157934,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21754,"output_tokens":9291,"usd":0.170522,"stage2_stop_reason":"end_turn"},"total_usd":0.328456,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"Heterozygous GATA2 missense mutations (p.Thr354Met, p.Thr355del) within the second zinc finger domain reduce DNA-binding affinity and transactivation of target genes, and differentially affect cellular differentiation and apoptosis, establishing haploinsufficiency as a mechanism of MDS-AML predisposition.\",\n      \"method\": \"Functional transactivation assays, cellular differentiation assays, apoptosis assays, global gene expression profiling of patient-derived mutations\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal functional assays (transactivation, differentiation, apoptosis, gene expression) in a peer-reviewed study identifying the founding mutations\",\n      \"pmids\": [\"21892162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"GATA2 is phosphorylated in hematopoietic progenitor cells; IL-3 stimulation enhances GATA2 phosphorylation within 5 minutes via the MAP kinase pathway, as demonstrated by constitutively activating and interfering MAP kinase kinase mutants; in vitro phosphorylation experiments raise the possibility that MAP kinase directly phosphorylates GATA2.\",\n      \"method\": \"In vivo phosphorylation assays in hematopoietic progenitors, genetic manipulation of MAP kinase pathway in COS cells (activating/interfering MEK mutants), in vitro phosphorylation with recombinant GATA2\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro kinase assay plus genetic epistasis in cells; two orthogonal approaches (genetic MEK manipulation + in vitro phosphorylation) from a single lab\",\n      \"pmids\": [\"7876160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"GATA2 expression oscillates during the cell cycle in hematopoietic cells (high in S phase, low in G1/S and M phase) due to proteasome-dependent degradation regulated by phosphorylation at Cdk-consensus (S/T-P) motifs; GATA2 physically interacts with Cdk2/cyclin A2 and Cdk4/cyclin D1 complexes and is phosphorylated by these in vitro; mutations at phosphorylation motifs alter cell-cycle-specific GFP-GATA2 expression profiles.\",\n      \"method\": \"Cell-cycle synchronization, GFP-GATA2 fusion protein imaging, immunoprecipitation/immunoblotting for Cdk interactions, in vitro phosphorylation by Cdk/cyclin, phosphorylation-site mutagenesis, proteasome inhibition\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods: in vitro kinase assay, Co-IP with Cdks, mutagenesis of phosphorylation sites, and proteasome inhibition; single lab but mechanistically comprehensive\",\n      \"pmids\": [\"17255359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Gata2, Fli1, and Scl/Tal1 form a fully connected recursive gene-regulatory circuit (triad) in hematopoietic stem cells; each of these transcription factors binds the enhancers of the other two (Gata2-3, Fli1+12, Scl+19) in embryonic dorsal aorta, fetal liver, and ES cell-derived hemangioblast equivalents.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) at multiple HSC enhancers, enhancer-reporter transgenic mice, cis-element motif analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal ChIP across three loci in multiple tissue contexts, validated by transgenic reporter assays; replicated across enhancer elements\",\n      \"pmids\": [\"17962413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"GATA2 is a direct transcriptional target of BMP4 in hemangioblast development; enforced GATA2 expression upregulates Bmp4, Flk1, and Scl; conditional GATA2 induction increases hemangioblast generation and endothelial cell production and confers a proliferative signal to primitive erythroid progenitors in a temporal-sensitive manner.\",\n      \"method\": \"ES cell differentiation system, conditional GATA2 induction, gene expression analysis, BMP4 stimulation experiments\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional gain-of-function with defined cellular phenotypes and upstream pathway placement; single lab\",\n      \"pmids\": [\"17166922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"GATA2 regulates granulocyte-macrophage progenitor (GMP) function through transcriptional activation of HES-1; GATA2 binds the HES-1 locus in myeloid progenitor cells, and enforced HES-1 expression in GATA2-heterozygous GMPs rescues the functional defect caused by GATA2 haploinsufficiency.\",\n      \"method\": \"GATA2+/- mouse analysis, RNA interference knockdown, colony-forming assays, competitive transplantation, ChIP at HES-1 locus, HES-1 forced expression rescue\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP at HES-1 locus, epistasis rescue experiment, genetic heterozygous model, and RNAi; multiple orthogonal methods\",\n      \"pmids\": [\"18840712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GATA2 function is essential for endothelial-to-hematopoietic transition (EHT) during HSC generation from VE-Cadherin-expressing endothelial cells, and is also required for HSC survival after generation in Vav-expressing hematopoietic cells; these two roles are genetically separable and distinct from RUNX1 function.\",\n      \"method\": \"Conditional Gata2 deletion using Vec-Cre (endothelial) and Vav-Cre (hematopoietic) lineage-specific mouse models, long-term repopulation assays, intra-aortic cluster analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent conditional KO systems with lineage-specific deletion, functional HSC assays (LT-repopulation), and epistatic comparison to RUNX1\",\n      \"pmids\": [\"24297996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"GATA2 loss in VE-enhancer-expressing endothelial cells causes anemia via HSC loss in fetal liver and defective lymphatic vascular development; the VE enhancer also regulates GATA2 expression in definitive fetal liver and adult bone marrow HSCs.\",\n      \"method\": \"Tamoxifen-inducible Cre transgenic mice (Gata2 VECre), in vitro colony-forming assays, immunophenotyping, in vivo long-term competitive repopulation, embryo morphology analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — inducible conditional KO with multiple functional readouts (colony, repopulation, lymphatic phenotype); rigorous mechanistic dissection\",\n      \"pmids\": [\"22996665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GATA2 directly promotes expression of both full-length and splice-variant androgen receptor (AR) in prostate cancer; GATA2 co-localizes with AR and FOXA1 on chromatin and enhances recruitment of steroid receptor coactivators (SRC) and formation of the transcriptional holocomplex; AR/androgen negatively regulates GATA2 in a feedback loop.\",\n      \"method\": \"ChIP, gene expression profiling, Co-IP, knockdown/overexpression experiments in prostate cancer cell lines, patient specimen correlation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating co-occupancy with AR and FOXA1, coactivator recruitment assays, and KD/OE with defined molecular phenotypes; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"25489091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GATA2 and LMO2 form transcriptional complexes in endothelial and lymphatic endothelial cells and cooperatively regulate VEGF-induced angiogenesis and lymphangiogenesis by directly activating neuropilin-2 (NRP2) gene expression at the promoter level; NRP2 overexpression partially rescues impaired angiogenic sprouting caused by GATA2/LMO2 knockdown.\",\n      \"method\": \"siRNA knockdown, lentiviral overexpression, angiogenic sprouting assays, NRP2 promoter analysis, NRP2 rescue experiments in endothelial and lymphatic endothelial cells\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — functional rescue experiment with NRP2, promoter analysis, and KD phenotype; single lab with multiple assays\",\n      \"pmids\": [\"23892628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Etv2 and Gata2 physically interact in vitro and in vivo; the protein-protein interaction is mediated by the Ets and GATA domains; co-expression of Gata2 augments Etv2 activity in promoting endothelial and hematopoietic lineage differentiation; Etv2 and Gata2 both bind the Spi1 promoter in vitro and in vivo.\",\n      \"method\": \"Co-immunoprecipitation in vitro and in vivo, embryoid body differentiation system, ChIP at Spi1 promoter, domain-deletion interaction mapping\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus ChIP for shared target; single lab, two orthogonal methods\",\n      \"pmids\": [\"24583263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"STAT5 directly binds the Gata2 promoter and an intronic region, transcriptionally activating Gata2; overexpression of Gata2 alone is sufficient to direct basophil and mast cell differentiation in the absence of Stat5, establishing GATA2 as a downstream effector in the STAT5-GATA2 pathway for basophil and mast cell differentiation.\",\n      \"method\": \"ChIP of STAT5 at Gata2 locus, Gata2 overexpression in Stat5-deficient cells, conditional knockout mice, differentiation assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP demonstrating direct STAT5 binding to Gata2 locus, genetic epistasis (rescue by Gata2 overexpression in Stat5-/- cells); multiple orthogonal methods\",\n      \"pmids\": [\"25801432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GATA2 regulates erythroid maturation through transcriptional repression of Gata2 by histone methyltransferase Setd8 (which monomethylates H4K20); Setd8 occupies regulatory elements in the Gata2 locus, and Setd8 knockdown leads to loss of H4K20me1 and gain of H4 acetylation at the Gata2 1S promoter, increasing GATA2 expression; Gata2 knockdown rescues maturation impairments caused by Setd8 disruption.\",\n      \"method\": \"Stable Setd8 knockdown in erythroblasts, global gene expression, ChIP for Setd8 occupancy and histone marks at Gata2 locus, Gata2 knockdown rescue experiments\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP for occupancy and histone marks at Gata2 locus, genetic rescue by Gata2 KD, and phenotypic characterization; multiple orthogonal methods from single lab\",\n      \"pmids\": [\"25848090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Uterine GATA2 directly occupies and promotes expression of the progesterone receptor (PGR) gene and co-regulates downstream progesterone-responsive genes in conjunction with PGR; uterine-specific Gata2 ablation causes infertility via impaired embryo implantation, decidualization failure, reduced PGR expression, and attenuated progesterone signaling.\",\n      \"method\": \"Uterine-specific conditional Gata2 knockout mice, genome-wide ChIP-seq (GATA2 occupancy at Pgr locus), RNA-seq, implantation and decidualization phenotyping\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with ChIP-seq and RNA-seq demonstrating direct GATA2 occupancy at Pgr and co-regulation of PGR target genes\",\n      \"pmids\": [\"27783953\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GATA2 deficiency in endothelial cells causes vascular abnormalities through regulation of miR-126 (pro-angiogenic) and miR-221 (anti-angiogenic); GATA2 transcriptionally activates miR-126 (which targets SPRED1 and FOXO3a) and suppresses miR-221 expression via DNA methylation of the miR-221 promoter CpG island; miR-221 silencing or miR-126 supplementation reverses the GATA2-deficient vascular phenotype.\",\n      \"method\": \"Endothelial siRNA knockdown and lentiviral overexpression, ChIP, luciferase promoter assays, bisulfite sequencing, proteome profiler, luciferase reporter gene assays, carotid injury mouse model with nanoparticle miR-126 delivery\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP, promoter luciferase assays, bisulfite sequencing, and in vivo mouse rescue; multiple orthogonal methods in single study\",\n      \"pmids\": [\"27780851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GATA2 is required for DC differentiation via the myeloid pathway; GATA2 binds an enhancer element 190-kb downstream of the Gata3 locus and represses Gata3 expression in DC progenitors; loss of GATA2 leads to reduced myeloid gene expression (including mafb) and increased T-lymphocyte gene expression (including Gata3 and Tcf7) in DC progenitors.\",\n      \"method\": \"Gata2 conditional knockout and haploinsufficient mice, in vitro DC generation from progenitors, expression profiling, luciferase reporter assay with Gata3 +190 enhancer and GATA sequence deletion\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with in vitro rescue, reporter assay with mutagenesis of GATA binding sites, and expression profiling; multiple orthogonal methods\",\n      \"pmids\": [\"27259979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GATA2 missense mutations in zinc finger 2 (gT354M, gR396Q, gR398W, gC373R) display reduced DNA-binding affinity and transactivation compared to wild-type; two mutants (gT354M and gC373R) bind PU.1 more strongly than wild-type GATA2, potentially perturbing differentiation through PU.1 sequestration; all mutants except sL359V fail to suppress colony formation and some skew cell fate to granulocytes.\",\n      \"method\": \"DNA-binding affinity assays, transactivation reporter assays, Co-immunoprecipitation with PU.1, colony formation assays, cell fate analysis\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro DNA-binding assay, Co-IP for PU.1 interaction, functional transactivation, and colony/differentiation assays; multiple orthogonal methods in single study\",\n      \"pmids\": [\"28642594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GATA2 N-finger (amino-terminal zinc finger) mutations decrease GATA2 chromatin occupancy and attenuate target gene regulation; in a genetic complementation assay in myeloid progenitors, GATA2 disease mutants fail to induce erythroid differentiation but unexpectedly promote myeloid differentiation and proliferation, indicating GATA2 mutations are not strictly loss-of-function and that haploinsufficiency does not fully explain pathogenesis.\",\n      \"method\": \"Genetic complementation assay in Gata2 -77 enhancer-mutant mouse myeloid progenitors, chromatin occupancy assays, erythroid and myeloid differentiation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic complementation assay with multiple GATA2 mutants tested for chromatin occupancy and differentiation phenotypes; mechanistically rigorous with multiple orthogonal readouts\",\n      \"pmids\": [\"30301799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A single-nucleotide mutation in the Ets motif of the GATA2 +9.5 intronic enhancer does not impair steady-state hematopoiesis but abrogates stem/progenitor cell regeneration following hematopoietic stress, revealing that a disease predisposition mutation can selectively inactivate enhancer regenerative activity while sparing developmental activity.\",\n      \"method\": \"Mouse knockin models of +9.5 enhancer Ets motif mutations, steady-state hematopoiesis analysis, stress-induced hematopoietic regeneration assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knockin mouse model with functional dissection of steady-state vs. stress hematopoiesis; well-controlled mechanistic study\",\n      \"pmids\": [\"30620726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GATA2 and PU.1 cooperatively activate Ms4a2 (FcεRIβ) gene expression in mast cells through distinct mechanisms: GATA2 exclusively binds the proximal -60-bp promoter region in a mast cell-specific manner, while both GATA2 and PU.1 share binding at a +10.4-kbp downstream enhancer with LDB1; PU.1 ablation reduces GATA2 binding at both sites; deletion of the +10.4-kbp region by genome editing completely abolishes Ms4a2 expression.\",\n      \"method\": \"ChIP-seq, siRNA knockdown, genome editing (deletion of +10.4-kbp enhancer), chromatin looping analysis, mast cell gene expression assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq, genome editing with complete functional ablation, KD epistasis; multiple orthogonal methods\",\n      \"pmids\": [\"31501274\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GATA2 controls lymphatic vascular development and lymphovenous valve morphogenesis by regulating expression of miR-126, which in turn controls cell junction molecules VE-cadherin and claudin 5; miR-126 overexpression in GATA2-depleted lymphatic endothelial cells significantly rescues cell junction defects.\",\n      \"method\": \"Conditional GATA2 knockout mouse, primary human lymphatic endothelial cell (HLEC) siRNA knockdown, miR-126 overexpression rescue, junction molecule immunostaining\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO in vivo plus in vitro HLEC KD with miR-126 rescue; multiple orthogonal models\",\n      \"pmids\": [\"31582413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GATA2 deletion of the murine -77 enhancer (human equivalent causes leukemia) downregulates GATA2 and blocks progenitor differentiation into erythrocytes, megakaryocytes, basophils, and granulocytes (but not macrophages); multiomics and single-cell analyses show the enhancer coordinates both pro-fate and anti-fate (innate immunity-linked) circuitry in individual progenitor cells; increasing GATA2 via the enhancer both promotes fate and abrogates a fate-suppressing innate immunity program.\",\n      \"method\": \"Murine Gata2 -77 enhancer deletion, multiomics (transcriptomics + chromatin), single-cell analysis, progenitor differentiation assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal -omics plus functional differentiation assays in well-validated enhancer-mutant model\",\n      \"pmids\": [\"32736380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GATA2 directly activates CGA transcription; secreted CGA binds EGFR and activates EGFR signaling conferring chemoresistance; EGFR signaling in turn induces GATA2 expression and phosphorylation, forming a positive feedback circuit; N-glycosylation of CGA at Asn52 and Asn78 is required for CGA stability, secretion, and EGFR interaction.\",\n      \"method\": \"Secretome screening, conditioned media experiments, EGFR signaling assays, GATA2 overexpression/knockdown, mutagenesis of CGA N-glycosylation sites, ChIP for GATA2 at CGA promoter, microRNA target assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for GATA2 at CGA promoter, epistatic circuit demonstrated by KD/OE and mutagenesis; single lab\",\n      \"pmids\": [\"35289315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GATA2 promotes chromatin accessibility at super-enhancers of mast cell identity genes and primes both typical and super-enhancers at genes that respond to antigenic stimulation; GATA2-bound sites are several-fold denser at super-enhancers than at typical enhancers in mast cells.\",\n      \"method\": \"GATA2 knockout mast cells, ATAC-seq, ChIP-seq for GATA2 binding at super-enhancers and typical enhancers, RNA-seq\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ATAC-seq and ChIP-seq in KO cells with RNA-seq; multiple orthogonal genomic methods\",\n      \"pmids\": [\"33479210\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HMGA1 transactivates GATA2 through sequences near the +9.5 developmental enhancer, increasing chromatin accessibility and recruiting active histone marks; silencing GATA2 recapitulates most phenotypes of HMGA1 depletion in MPN cells, and GATA2 re-expression partially rescues leukemogenesis after HMGA1 loss.\",\n      \"method\": \"CRISPR/Cas9 disruption, shRNA knockdown, RNA-seq, ChIP-seq (HMGA1 occupancy at +9.5 GATA2 enhancer), chromatin accessibility assays, GATA2 rescue experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq at GATA2 enhancer, genetic rescue with GATA2 re-expression, KD/KO with multiple phenotypic readouts\",\n      \"pmids\": [\"35286385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GATA2 undergoes mitotic bookmarking via C-terminal zinc finger-mediated DNA binding, remaining bound to chromatin throughout mitosis in contrast to GFI1B and FOS; it bookmarks a subset of interphase targets co-enriched for RUNX1; conditional GATA2 degradation at mitotic exit in mice (cyclin B1 degradation domain knockin) abolishes definitive haematopoiesis at AGM, placenta, and fetal liver without impairing yolk sac haematopoiesis.\",\n      \"method\": \"Live-cell imaging, GATA2-cyclin B1 degradation domain knockin mouse model, ChIP during mitosis vs. interphase, domain-deletion experiments (C-terminal zinc finger), multiomics\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knockin mouse model plus mechanistic dissection of ZF domain requirement and genome-wide chromatin occupancy during mitosis; multiple orthogonal methods\",\n      \"pmids\": [\"37580379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GATA2 positively autoregulates its own transcription in the mouse midbrain through two discrete promoter domains (5H at -3.0 kbp and 2H at -1.9 kbp upstream of TSS) that both contain GATA factor binding sites; GATA2 (but not GATA3) is essential for Gata2 gene expression in the midbrain.\",\n      \"method\": \"Transgenic reporter mice, in vivo deletion analysis of promoter domains, Gata2/Gata3 knockout analyses, domain-specific reporter constructs\",\n      \"journal\": \"Genes to cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo transgenic reporter assay with genetic KO epistasis; single lab\",\n      \"pmids\": [\"19371385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GATA2 directly binds to the SEMA3C androgen response element in a GATA2-dependent manner, and AR-mediated transcriptional activation of SEMA3C requires GATA2; FOXA1 is a negative regulator of SEMA3C expression in the same context.\",\n      \"method\": \"ChIP for GATA2 and AR at SEMA3C locus, GATA2 knockdown in LNCaP cells, androgen stimulation experiments, luciferase reporter assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and KD with defined target gene phenotype; single lab, two methods\",\n      \"pmids\": [\"28038451\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GATA2 directly represses GATA6 expression in gastric cancer cells by recruiting the PRC2 complex to the GATA6 locus; disruption of GATA2 expression impairs PRC2 recruitment and results in GATA6 upregulation; GATA2 and PRC2 complexes are enriched within the GATA6 locus as demonstrated by ChIP.\",\n      \"method\": \"ChIP for GATA2 and PRC2 at GATA6 locus, GATA2 overexpression and knockdown, ectopic expression, bisulfite methylation analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating co-occupancy and epistatic KD/OE; single lab\",\n      \"pmids\": [\"29106391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GATA2 transcriptionally activates the Gata2 locus in endothelial haemogenic cells partly through the i4 pan-endothelial enhancer in zebrafish; deletion of the i4 enhancer reduces Gata2a, which in turn reduces runx1 and gata2b expression in hemogenic endothelium, and recovery is mediated by Notch signalling.\",\n      \"method\": \"CRISPR/Cas9 deletion of i4 enhancer in zebrafish, expression analysis of runx1/gata2b, Notch pathway analysis, adult hematopoiesis phenotyping\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo enhancer deletion with epistatic analysis of downstream targets; single lab\",\n      \"pmids\": [\"32054973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In vivo time-lapse imaging reveals that Gata2 reporter expression shows rapid pulsatile level changes in individual cells undergoing endothelial-to-hematopoietic transition (EHT) in the aorta; Gata2 haploinsufficient cells exhibit fewer transitions and reduced hematopoietic potential, suggesting threshold levels of Gata2 control fate establishment.\",\n      \"method\": \"Gata2Venus knock-in reporter mouse, time-lapse live imaging of aortic cells during EHT, single-cell quantitative fluorescence analysis, comparison with Gata2 heterozygous aortic cells\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct live imaging of endogenous GATA2 dynamics in single cells during fate transition, with functional comparison to haploinsufficient cells; novel mechanistic insight with direct experimental evidence\",\n      \"pmids\": [\"29217535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"GATA2 transcriptionally regulates RASSF4, a modulator of the p53 inhibitor MDM2, thereby dampening p53-mediated apoptosis; GATA2 deletion results in more robust p53 induction after doxorubicin exposure; RASSF4 and GATA2 are anticorrelated in AML; knockdown of Rassf4 in Gata2-low cells confers doxorubicin resistance; overexpression of Rassf4 sensitizes Gata2-high cells.\",\n      \"method\": \"ChIP-seq, RNA-seq, GATA2 deletion (CRISPR/Cas9), Rassf4 knockdown and overexpression, doxorubicin sensitivity assays, nutlin-3 experiments, single-cell and bulk patient expression data\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq demonstrating direct GATA2 binding at RASSF4 locus, genetic epistasis (Gata2 KO + Rassf4 KD/OE), functional drug resistance assays; multiple orthogonal methods\",\n      \"pmids\": [\"39841459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Progesterone receptor B (PGR-B) drives Ednra gene activation through one of six progesterone response elements (PRE6) in a conserved upstream region; GATA2 activity at a GATA2 site in the same region is required for the progesterone response, and GATA2 synergizes with PGR-B to enhance Ednra expression.\",\n      \"method\": \"In vivo pregnancy/progesterone experiments, promoter deletion analysis, luciferase reporter assays, GATA2 site mutagenesis\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter assays with GATA2 site mutagenesis and in vivo validation; single lab\",\n      \"pmids\": [\"23592430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GATA2 is not required for VE-cadherin+CD43-CD73- hemogenic endothelium (HE) specification or HE diversification into DLL4+ arterial and DLL4- non-arterial lineages, but is primarily required for HE to undergo endothelial-to-hematopoietic transition (EHT); forced GATA2 expression in non-HE failed to induce blood formation.\",\n      \"method\": \"GATA2 knockout hESC lines with conditional GATA2 expression (iG2-/- hESCs), hematopoietic differentiation assays, flow cytometry for HE and hematopoietic progenitor phenotypes\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO in human ESCs with rescue and gain-of-function, defining specific developmental stage of GATA2 requirement\",\n      \"pmids\": [\"29861167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GATA2 functions as a tumor suppressor in acute promyelocytic leukemia (APL); biallelic Gata2 knockout by CRISPR/Cas9 increases serial replating efficiency of PML-RARA-expressing progenitors, increases APL penetrance, and decreases latency; restoration of Gata2 suppresses PML-RARA-driven aberrant self-renewal; a mutant GATA2-R362G (associated with APL/AML) minimally suppresses PML-RARA-induced self-renewal, indicating it is a loss-of-function mutation.\",\n      \"method\": \"CRISPR/Cas9 Gata2 biallelic knockout, serial replating assays, mouse leukemia model (penetrance/latency), Gata2 restoration experiments, mutant addback experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — biallelic KO with CRISPR, in vivo leukemia model, rescue by WT and mutant addback; multiple orthogonal approaches\",\n      \"pmids\": [\"34125173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GATA2 hypomorphism (reduced Gata2 expression by neocassette insertion) in mice induces chronic myelomonocytic leukemia-like disease characterized by granulomonocytosis, trilineage dysplasia, impaired HSC reconstitution activity, and myeloid lineage-biased proliferation; GATA2 hypomorphic progenitors show increased expression of CSF1R and IL6R, correlating with hypersensitive granulomonocytic proliferation.\",\n      \"method\": \"Gata2 hypomorphic mouse model (neocassette knockin), competitive transplantation, gene expression analysis of myeloid progenitors, LPS challenge experiments\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo hypomorphic mouse model with transplantation and molecular analysis; single lab\",\n      \"pmids\": [\"30710465\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Noncoding heterozygous duplications within a neuron-specific GATA2 regulatory region (including two enhancers and one silencer) or SNVs within the silencer cause hereditary congenital facial paresis (HCFP1) by extending GATA2 expression; some SNVs impair NR2F1 binding to the silencer in vitro and in vivo, attenuating enhancer reporter expression in facial branchial motor neurons; a humanized HCFP1 mouse model confirms that extended Gata2 expression favors IEE over FBMN formation, rescued by conditional loss of Gata3.\",\n      \"method\": \"Human genetic mapping, humanized HCFP1 knockin mouse model, in vitro and in vivo NR2F1 binding assays, enhancer reporter assays in FBMNs, Gata3 conditional knockout rescue\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — humanized mouse model, in vitro and in vivo binding assays, genetic rescue by Gata3 KO; multiple orthogonal methods\",\n      \"pmids\": [\"37386251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GATA2 and progesterone receptor (PGR) co-occupy and co-regulate genes during human endometrial stromal cell decidualization; the PGR motif is highly enriched at GATA2 binding regions surrounding upregulated genes; GATA2 binding is enhanced at PGR-binding regions during decidualization, with co-regulation of WNT activation and stem cell differentiation pathways.\",\n      \"method\": \"RNA-seq, ChIP-seq (GATA2 cistrome in decidualization), integration with mined PGR ChIP-seq, pathway analysis\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq and RNA-seq integration showing co-occupancy; single lab\",\n      \"pmids\": [\"32335672\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GATA2 is required for GATA2 target gene GATA2 own transcription in the midbrain via GATA binding sites in the promoter; Gata2 promotes definitive haematopoiesis by directly binding GATA motifs within target gene regulatory regions.\",\n      \"method\": \"Referenced in context of broader auto-regulatory mechanism\",\n      \"journal\": \"IUBMB life\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — this is a review paper summarizing prior findings without independent experimental data; included only for completeness but confidence is low\",\n      \"pmids\": [\"31675473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Zebrafish Pur alpha functions as a repressor and Sp8 as an activator of neural gata2 expression during embryogenesis, as demonstrated by knockdown and ectopic expression experiments.\",\n      \"method\": \"Morpholino knockdown of Pur alpha and Sp8 in zebrafish, ectopic expression, gata2 neural expression analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KD and OE with defined gata2 expression phenotype in zebrafish neural tissue; single lab\",\n      \"pmids\": [\"15464585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GATA2 regulates constitutive PD-L2 expression in brain tumors; GATA2 is sufficient to drive both PD-L1 and PD-L2 expression and is necessary for PD-L2 expression, as demonstrated by characterization of novel cis-regulatory regions in CD274 and PDCD1LG2 using luciferase assays and perturbation of GATA2.\",\n      \"method\": \"Luciferase assays with CD274/PDCD1LG2 cis-regulatory regions, GATA2 overexpression and knockdown in brain tumor cell lines and BTICs, flow cytometry for PD-L1/PD-L2\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — luciferase reporter assays with KD/OE phenotype; single lab, limited mechanistic depth\",\n      \"pmids\": [\"32493985\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GATA2 is a zinc-finger transcription factor and pioneer factor that directly binds GATA DNA motifs to activate or repress target genes in a cell-type-specific manner; it undergoes cell-cycle-dependent proteasomal degradation regulated by Cdk/cyclin-mediated phosphorylation at S/T-P motifs, is phosphorylated by the MAP kinase pathway downstream of IL-3 signaling, participates in a recursive auto-regulatory and cross-regulatory circuit with Fli1 and Scl in HSCs, undergoes mitotic bookmarking via its C-terminal zinc finger to maintain definitive hematopoietic fate inheritance, regulates HSC generation specifically during endothelial-to-hematopoietic transition and is separately required for HSC survival, activates target genes including AR (in prostate cancer), NRP2 (in endothelial/lymphatic cells), miR-126 and miR-221 (in vascular biology), RASSF4 (dampening p53-mediated apoptosis), HES-1 (in myeloid progenitors), and represses GATA6 (via PRC2 recruitment) and Gata3 (in DC progenitors); its own transcription is repressed by Setd8-mediated H4K20 monomethylation and activated by STAT5 binding to the Gata2 promoter.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GATA2 is a zinc-finger transcription factor that orchestrates the specification, generation, and survival of hematopoietic stem cells and governs differentiation programs across hematopoietic, endothelial, and reproductive tissues by binding GATA DNA motifs to activate or repress target genes in a cell-type-specific, dosage-sensitive manner [#3, #6, #17]. In hematopoietic stem cells it operates within a fully connected recursive triad with Fli1 and Scl/Tal1, in which each factor binds the others' enhancers [#3], and it is genetically required for the endothelial-to-hematopoietic transition that generates HSCs as well as for their subsequent survival, two separable functions distinct from RUNX1 [#6, #33]; threshold GATA2 levels, which pulse in individual cells during this transition, set the probability of fate establishment [#30]. GATA2 directs lineage choices by activating pro-fate targets such as HES-1 in granulocyte-macrophage progenitors [#5] and by repressing alternative-fate genes, including Gata3 in dendritic-cell progenitors through a downstream enhancer [#15] and GATA6 via PRC2 recruitment [#28]. Its action is dosage- and context-dependent, integrating chromatin and enhancer logic: it increases chromatin accessibility at mast-cell super-enhancers [#23], cooperates with PU.1 and LDB1 at composite enhancers to activate Ms4a2 [#19], and remains bound to chromatin through mitosis via its C-terminal zinc finger to bookmark RUNX1-co-enriched targets and propagate definitive hematopoietic fate [#25]. GATA2 protein abundance is controlled by cell-cycle-dependent, Cdk/cyclin-mediated phosphorylation at S/T-P motifs driving proteasomal degradation [#2] and by MAP-kinase phosphorylation downstream of IL-3 [#1], while its transcription is set by STAT5 [#11], by autoregulation through GATA sites [#26], and by repressive Setd8-mediated H4K20 monomethylation [#12]. Beyond hematopoiesis, GATA2 partners with the progesterone receptor to drive uterine PGR expression and decidualization [#13, #37] and controls endothelial and lymphatic development through miR-126 and miR-221 [#14, #20]. Heterozygous zinc-finger missense mutations reduce DNA binding and transactivation, establishing GATA2 haploinsufficiency as a mechanism of MDS-AML predisposition, with some mutants additionally sequestering PU.1 and exerting non-loss-of-function effects [#0, #16, #17]; GATA2 also acts as a tumor suppressor restraining PML-RARA-driven self-renewal in acute promyelocytic leukemia [#34], and noncoding mutations that extend GATA2 expression in facial branchial motor neurons cause hereditary congenital facial paresis [#36].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established that GATA2 activity is acutely regulated by signaling, linking cytokine input to transcription-factor modification rather than treating GATA2 as a static regulator.\",\n      \"evidence\": \"In vivo phosphorylation in hematopoietic progenitors, MEK mutant epistasis in COS cells, and in vitro phosphorylation of recombinant GATA2\",\n      \"pmids\": [\"7876160\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct MAP kinase phosphorylation site on GATA2 not definitively mapped\", \"Functional consequence of IL-3-induced phosphorylation on target gene output unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Placed GATA2 downstream of BMP4 and upstream of hemangioblast/endothelial programs, defining its role in early blood/vessel fate commitment.\",\n      \"evidence\": \"ES cell differentiation with conditional GATA2 induction and BMP4 stimulation\",\n      \"pmids\": [\"17166922\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct GATA2 occupancy at Bmp4/Flk1/Scl loci not shown here\", \"Temporal-window dependence not mechanistically explained\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed GATA2 abundance oscillates with the cell cycle via Cdk/cyclin phosphorylation and proteasomal turnover, revealing post-translational control of a master hematopoietic factor.\",\n      \"evidence\": \"Cell-cycle synchronization, Co-IP with Cdk2/cyclinA2 and Cdk4/cyclinD1, in vitro Cdk phosphorylation, site mutagenesis, proteasome inhibition\",\n      \"pmids\": [\"17255359\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase mediating GATA2 degradation not identified\", \"Functional output of cell-cycle-phased GATA2 levels on target genes unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined the Gata2-Fli1-Scl recursive triad, providing the architecture for how HSC identity is stably maintained through mutual cross-activation.\",\n      \"evidence\": \"Reciprocal ChIP at three HSC enhancers across embryonic and ES-derived contexts with transgenic reporters\",\n      \"pmids\": [\"17962413\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of each triad edge to HSC maintenance not dissected\", \"Dynamics of circuit establishment during EHT not addressed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified HES-1 as a functional GATA2 target whose restoration rescues haploinsufficient progenitor defects, providing a concrete effector for GATA2 dosage phenotypes.\",\n      \"evidence\": \"GATA2+/- mice, ChIP at HES-1 locus, RNAi, colony/transplantation assays, HES-1 forced-expression rescue\",\n      \"pmids\": [\"18840712\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HES-1 accounts for all GMP defects unclear\", \"Direct binding site within HES-1 locus not finely mapped\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrated direct GATA2 positive autoregulation through defined promoter GATA sites in a non-hematopoietic (midbrain) context, generalizing self-reinforcement of GATA2 expression.\",\n      \"evidence\": \"Transgenic reporter mice with promoter-domain deletion and Gata2/Gata3 KO epistasis\",\n      \"pmids\": [\"19371385\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the same promoter domains drive hematopoietic autoregulation untested here\", \"Single-lab in vivo reporter system\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established GATA2 haploinsufficiency as a mechanism of MDS-AML predisposition by showing founding zinc-finger mutations reduce DNA binding and transactivation.\",\n      \"evidence\": \"Transactivation, differentiation, apoptosis, and gene expression assays on patient-derived ZF2 mutations\",\n      \"pmids\": [\"21892162\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo leukemogenic mechanism not modeled in this study\", \"Cell-of-origin and second-hit requirements unaddressed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Genetically separated GATA2's role in HSC generation during EHT from its requirement in HSC survival, refining when and where GATA2 acts and distinguishing it from RUNX1.\",\n      \"evidence\": \"Vec-Cre and Vav-Cre conditional Gata2 deletion with LT-repopulation and aortic cluster analysis\",\n      \"pmids\": [\"24297996\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Survival-stage target genes not defined\", \"Molecular distinction from RUNX1 at the target level unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended GATA2 function beyond hematopoiesis by showing it forms complexes with LMO2 to activate NRP2 and drive angiogenesis/lymphangiogenesis.\",\n      \"evidence\": \"siRNA/overexpression, sprouting assays, NRP2 promoter analysis and rescue in endothelial cells\",\n      \"pmids\": [\"23892628\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct GATA2-LMO2 physical interaction not biochemically resolved here\", \"Partial NRP2 rescue implies additional effectors\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed GATA2 as a context-dependent repressor recruiting PRC2 to silence GATA6, expanding its mechanistic repertoire to Polycomb-mediated repression.\",\n      \"evidence\": \"ChIP for GATA2 and PRC2 at GATA6 locus with KD/OE and bisulfite analysis in gastric cancer cells\",\n      \"pmids\": [\"29106391\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct GATA2-PRC2 contact not demonstrated\", \"Single cancer-cell context\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified GATA2 as a driver of androgen receptor expression and a chromatin co-factor with AR/FOXA1 in prostate cancer, defining an oncogenic transcriptional role.\",\n      \"evidence\": \"ChIP co-occupancy, Co-IP, coactivator recruitment, KD/OE in prostate cancer cells with patient correlation\",\n      \"pmids\": [\"25489091\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs. indirect coactivator bridging not separated\", \"Generalizability beyond prostate lineage untested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed GATA2 physically partners with Etv2 via GATA/Ets domains to co-activate shared endothelial/hematopoietic targets, providing a protein-level cooperativity mechanism.\",\n      \"evidence\": \"Reciprocal Co-IP, domain-mapping, embryoid-body differentiation, ChIP at Spi1 promoter\",\n      \"pmids\": [\"24583263\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Genome-wide co-occupancy not assessed\", \"Functional necessity of the interaction in vivo not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Placed GATA2 downstream of STAT5 as a direct transcriptional target sufficient to drive basophil/mast-cell fate, connecting cytokine signaling to GATA2-driven differentiation.\",\n      \"evidence\": \"STAT5 ChIP at Gata2 locus and Gata2 overexpression rescue in Stat5-deficient cells\",\n      \"pmids\": [\"25801432\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other STAT5-independent inputs to Gata2 not delineated\", \"Lineage breadth of this pathway beyond basophil/mast cell unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined repressive epigenetic control of the Gata2 locus by Setd8/H4K20me1 during erythroid maturation, showing Gata2 silencing is required for differentiation.\",\n      \"evidence\": \"Setd8 knockdown, ChIP for occupancy and histone marks at Gata2 locus, Gata2 KD rescue in erythroblasts\",\n      \"pmids\": [\"25848090\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Setd8 is targeted to the Gata2 locus unknown\", \"Whether this mechanism operates in HSCs untested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established GATA2 as a uterine regulator activating PGR and progesterone signaling, defining a reproductive function essential for implantation and decidualization.\",\n      \"evidence\": \"Uterine conditional Gata2 KO with ChIP-seq at Pgr and RNA-seq, implantation/decidualization phenotyping\",\n      \"pmids\": [\"27783953\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream regulators of uterine GATA2 not defined\", \"GATA2-PGR physical interaction not addressed here\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed GATA2 controls vascular integrity through opposing regulation of miR-126 and miR-221, including DNA-methylation-mediated silencing, broadening its endothelial effector network.\",\n      \"evidence\": \"Endothelial KD/OE, ChIP, luciferase, bisulfite sequencing, and in vivo carotid-injury miR-126 rescue\",\n      \"pmids\": [\"27780851\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which GATA2 directs miR-221 promoter methylation unclear\", \"Relative contribution of each miRNA arm in vivo not partitioned\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated GATA2 represses Gata3 via a long-range enhancer to enforce myeloid over lymphoid identity in dendritic-cell progenitors.\",\n      \"evidence\": \"Conditional/haploinsufficient mice, in vitro DC generation, reporter assays with GATA-site mutagenesis at Gata3 +190\",\n      \"pmids\": [\"27259979\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-repressors mediating Gata3 silencing not identified\", \"Direct vs. indirect myeloid gene activation not fully separated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Refined the GATA2 mutation model by showing ZF2 mutants not only lose DNA binding but can gain PU.1 sequestration, indicating effects beyond simple haploinsufficiency.\",\n      \"evidence\": \"DNA-binding, transactivation, Co-IP with PU.1, colony and cell-fate assays on multiple mutants\",\n      \"pmids\": [\"28642594\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of enhanced PU.1 binding untested\", \"Allele-specific clinical correlation not established\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed GATA2 is required for AR-driven SEMA3C activation, reinforcing its role as an obligate co-factor in androgen-responsive transcription.\",\n      \"evidence\": \"ChIP for GATA2/AR at SEMA3C, GATA2 KD, androgen stimulation, luciferase assays in LNCaP\",\n      \"pmids\": [\"28038451\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of FOXA1 antagonism not resolved\", \"Single-cell-line context\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated that disease-associated N-finger mutations reduce chromatin occupancy yet can promote myeloid differentiation, showing GATA2 pathogenesis is not strictly loss-of-function.\",\n      \"evidence\": \"Genetic complementation in -77 enhancer-mutant myeloid progenitors with occupancy and differentiation readouts\",\n      \"pmids\": [\"30301799\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of myeloid-promoting gain-of-function unclear\", \"Relationship to leukemic transformation not directly tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Dissected enhancer-specific functions, showing the +9.5 Ets motif is dispensable for steady-state but essential for stress regeneration, separating developmental from regenerative GATA2 activity.\",\n      \"evidence\": \"Mouse knockin of +9.5 Ets-motif mutations with steady-state vs. stress hematopoiesis assays\",\n      \"pmids\": [\"30620726\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stress-specific transcription factors acting at +9.5 not identified\", \"Molecular basis of regeneration-selective requirement unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined composite enhancer logic in mast cells, showing GATA2 and PU.1 cooperate with LDB1 at a downstream enhancer essential for Ms4a2, with PU.1 supporting GATA2 binding.\",\n      \"evidence\": \"ChIP-seq, siRNA, genome-editing deletion of +10.4-kbp enhancer, chromatin looping\",\n      \"pmids\": [\"31501274\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Hierarchy of GATA2/PU.1/LDB1 assembly not fully ordered\", \"Generality across mast-cell genes untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed GATA2 governs lymphatic valve morphogenesis through miR-126 control of junctional molecules, linking GATA2 to endothelial barrier architecture.\",\n      \"evidence\": \"Conditional GATA2 KO mouse and HLEC siRNA with miR-126 overexpression rescue and junction immunostaining\",\n      \"pmids\": [\"31582413\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct GATA2 occupancy at junction genes vs. miR-126-mediated effect not fully separated\", \"Valve-specific co-factors unidentified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Modeled GATA2 hypomorphism as causing CMML-like disease with myeloid bias and cytokine-receptor upregulation, connecting reduced dosage to specific malignant phenotypes.\",\n      \"evidence\": \"Gata2 hypomorphic neocassette mice with transplantation, expression analysis, LPS challenge\",\n      \"pmids\": [\"30710465\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct GATA2 regulation of CSF1R/IL6R not demonstrated\", \"Single-lab model\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Pinpointed the precise developmental window of GATA2 requirement to the EHT step of hemogenic endothelium, showing it is dispensable for HE specification and diversification.\",\n      \"evidence\": \"GATA2 KO hESC lines with conditional/forced expression and hematopoietic differentiation assays\",\n      \"pmids\": [\"29861167\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Targets executing the EHT step not catalogued\", \"Why forced GATA2 cannot reprogram non-HE unexplained\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Used multiomics to show the -77 enhancer coordinates both pro-fate and innate-immunity anti-fate circuits, reframing GATA2 dosage as balancing opposing programs in single progenitors.\",\n      \"evidence\": \"Murine -77 enhancer deletion with single-cell multiomics and differentiation assays\",\n      \"pmids\": [\"32736380\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the fate-suppressing innate immunity effectors incomplete\", \"Mechanism linking GATA2 level to immunity program off-switch unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed conserved enhancer-driven Gata2 autoactivation in zebrafish hemogenic endothelium feeds into runx1 and Notch circuitry, generalizing GATA2 positive autoregulation in blood development.\",\n      \"evidence\": \"CRISPR i4 enhancer deletion with downstream runx1/gata2b expression and Notch analysis\",\n      \"pmids\": [\"32054973\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct GATA2 binding at i4 not shown here\", \"Mapping to mammalian enhancers uncertain\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established genome-wide GATA2-PGR co-occupancy as the basis of decidualization gene regulation, deepening the GATA2 reproductive mechanism.\",\n      \"evidence\": \"GATA2 ChIP-seq and RNA-seq integrated with PGR ChIP-seq in human endometrial stromal cells\",\n      \"pmids\": [\"32335672\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct GATA2-PGR physical interaction not tested\", \"Causality of co-binding vs. sequential binding unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed GATA2 establishes chromatin accessibility at mast-cell super-enhancers and primes antigen-responsive loci, framing it as a determinant of enhancer landscape and identity.\",\n      \"evidence\": \"GATA2 KO mast cells with ATAC-seq, ChIP-seq, and RNA-seq\",\n      \"pmids\": [\"33479210\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GATA2 acts as a pioneer factor at these sites not directly demonstrated\", \"Order relative to other identity factors unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined GATA2 as a tumor suppressor restraining PML-RARA-driven self-renewal, with the R362G allele confirmed as loss-of-function in APL.\",\n      \"evidence\": \"CRISPR biallelic Gata2 KO, serial replating, mouse leukemia penetrance/latency, WT and mutant addback\",\n      \"pmids\": [\"34125173\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Target genes mediating self-renewal suppression not identified\", \"Interaction with PML-RARA at chromatin not characterized\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Placed GATA2 downstream of HMGA1 as a target whose re-expression partially rescues leukemogenesis, linking it to a chromatin-accessibility regulatory axis in MPN.\",\n      \"evidence\": \"CRISPR/shRNA, RNA-seq, HMGA1 ChIP-seq at +9.5 GATA2 enhancer, accessibility assays, GATA2 rescue\",\n      \"pmids\": [\"35286385\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why GATA2 re-expression only partially rescues unresolved\", \"Context-dependence (tumor-suppressor vs. oncogenic) of GATA2 in myeloid disease not reconciled\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated GATA2 mitotic bookmarking via the C-terminal zinc finger maintains definitive hematopoietic fate, providing a mechanism for heritable transcriptional memory through cell division.\",\n      \"evidence\": \"Live imaging, GATA2-cyclinB1 degron knockin mouse, mitotic vs. interphase ChIP, ZF domain deletion, multiomics\",\n      \"pmids\": [\"37580379\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How bookmarked targets are reactivated post-mitosis not detailed\", \"Functional role of RUNX1 co-enrichment at bookmarked sites untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Linked noncoding GATA2 regulatory mutations that extend its expression in facial motor neurons to hereditary congenital facial paresis, establishing a gain-of-expression neurodevelopmental disease mechanism.\",\n      \"evidence\": \"Human genetic mapping, humanized HCFP1 mouse, NR2F1 binding assays, FBMN reporter assays, Gata3 KO rescue\",\n      \"pmids\": [\"37386251\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full set of GATA2 targets driving FBMN-to-IEE fate shift unresolved\", \"Generalizability of silencer/enhancer logic to other GATA2-dependent tissues unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified RASSF4 as a GATA2 target that dampens p53-mediated apoptosis, providing a mechanism by which GATA2 levels modulate chemoresistance in AML.\",\n      \"evidence\": \"ChIP-seq, RNA-seq, CRISPR GATA2 deletion, Rassf4 KD/OE, doxorubicin and nutlin-3 assays, patient data\",\n      \"pmids\": [\"39841459\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct RASSF4-MDM2-p53 biochemical link not shown here\", \"Therapeutic exploitability across GATA2-mutant subtypes untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How GATA2 dosage and the same DNA-binding activity are reconciled across opposing roles — pro-fate activator vs. anti-fate repressor, tumor suppressor vs. oncogenic AR co-factor — remains unresolved at the level of context-defining co-factors and chromatin state.\",\n      \"evidence\": \"No single study reconciles the divergent context-dependent outputs\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified model linking GATA2 partner identity to activator vs. repressor output\", \"E3 ligase and full post-translational control network incomplete\", \"Determinants of tissue-specific enhancer selection not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 3, 5, 13, 23, 28]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 16, 17, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 25]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [25, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 3, 5, 13, 23, 28]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 6, 33, 30]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 34, 36]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [12, 23, 25, 28]}\n    ],\n    \"complexes\": [\"PRC2 (recruited by GATA2 at GATA6 locus)\", \"Gata2-Fli1-Scl HSC triad\"],\n    \"partners\": [\"FLI1\", \"TAL1\", \"PU.1\", \"LMO2\", \"ETV2\", \"PGR\", \"FOXA1\", \"AR\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}